0001628280-21-016321 | 10-Q | XBRL Viewer

^[1]

4,384,348

Ending balance (in shares) at Mar. 31, 2020

$ 40,016

^[1]

4,384,348

Ending balance at Mar. 31, 2020

$ 40,016

^[1]

7,902,407

Increase (Decrease) in Stockholders' Equity [Roll Forward]

$ (100,319)

$ 0

$ 2,320

$ (44)

$ (102,595)

Issuance of common stock upon exercise of stock options (in shares)

^[1]

423

Issuance of common stock upon exercise of stock options

$ 2

175

Reclassification of a note receivable from a stockholder

(18,693)

Ending balance (in shares) at Mar. 31, 2020

^[1]

7,902,830

Ending balance at Mar. 31, 2020

(118,779)

2,509

(121,288)

^[1]

4,384,348

$ 40,016

^[1]

42,102,255

$ 18,330

^[1]

7,902,407

Increase (Decrease) in Stockholders' Equity [Roll Forward]

(100,319)

$ 0

2,320

(44)

(102,595)

(30,005)

^[1]

24,379,580

Beginning balance (in shares) at Mar. 31, 2020

(11,292)

$ 0

121,308

(132,600)

^[1]

4,384,348

Beginning balance at Mar. 31, 2020

$ 40,016

Increase (Decrease) in Temporary Equity [Roll Forward]

Issuance of redeemable convertible preferred stock (in shares)

^[1]

43,952,862

Issuance of redeemable convertible preferred stock

$ 18,330

Conversion of redeemable convertible preferred stock to common stock (in shares)

^[1]

(6,234,955)

Conversion of redeemable convertible preferred stock to common stock

$ (40,016)

^[1]

42,102,255

Beginning balance (in shares) at Mar. 31, 2020

$ 18,330

^[1]

7,902,830

Beginning balance at Mar. 31, 2020

(118,779)

2,509

(121,288)

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Conversion of redeemable convertible preferred stock to common stock (in shares)

^[1]

6,234,955

Conversion of redeemable convertible preferred stock to common stock

40,016

$ 0

40,016

460

Conversion of convertible notes to common stock (in shares)

(11,312)

^[1]

10,241,795

Conversion of convertible notes to common stock

78,311

^[1]

24,379,580

$ (11,292)

$ 0

121,308

(132,600)

88,434,754

^[1]

Increase (Decrease) in Temporary Equity [Roll Forward]

$ 39,225

Issuance of redeemable convertible preferred stock (in shares)

^[1]

4,232,947

Issuance of redeemable convertible preferred stock

$ 58,097

Conversion of redeemable convertible preferred stock to common stock (in shares)

^[1]

(92,667,701)

Conversion of redeemable convertible preferred stock to common stock

$ (97,322)

Ending balance (in shares) at Mar. 31, 2021

^[1]

Ending balance at Mar. 31, 2021

$ 0

33,327,294

^[1]

Increase (Decrease) in Stockholders' Equity [Roll Forward]

$ (75,907)

$ 0

133,468

(209,375)

Issuance of common stock upon exercise of stock options (in shares)

^[1]

727,114

Issuance of common stock upon exercise of stock options

190

$ 1

189

Repurchase of common stock (shares)

^[1]

(220,561)

Repurchase of common stock

(43)

Conversion of redeemable convertible preferred stock to common stock (in shares)

^[1]

92,667,701

Conversion of redeemable convertible preferred stock to common stock

$ 97,334

$ 12

97,322

Issuance of common stock upon merger and private offering, net of acquired private placement warrants of $19,377 (in shares)

^[1]

34,947,657

Issuance of common stock upon merger and private offering, net of acquired private placement warrants of $19,377

$ 272,064

$ 3

272,061

Offering costs in connection with the merger

(26,620)

438

5,256

Ending balance (in shares) at Mar. 31, 2021

(20,957)

^[1]

161,449,205

Ending balance at Mar. 31, 2021

$ 251,755

$ 16

482,071

(230,332)

88,434,754

^[1]

$ 39,225

$ 0

33,327,294

^[1]

Increase (Decrease) in Stockholders' Equity [Roll Forward]

$ (75,907)

$ 0

133,468

(209,375)

Issuance of common stock upon exercise of stock options (in shares)

727,116

$ (52,968)

161,449,205

^[1]

Beginning balance (in shares) at Mar. 31, 2021

$ 226,002

$ 16

488,329

(262,343)

^[1]

Beginning balance at Mar. 31, 2021

$ 0

Beginning balance (in shares) at Mar. 31, 2021

$ 0

^[1]

161,449,205

Beginning balance at Mar. 31, 2021

251,755

$ 16

482,071

(230,332)

Increase (Decrease) in Stockholders' Equity [Roll Forward]

104

6,154

$ (32,011)

(32,011)

161,449,205

^[1]

Summary of Significant Accounting Policies

$ 226,002

$ 16

$ 488,329

$ 0

$ (262,343)

[1]	The shares of the Company’s common and redeemable convertible preferred stock, prior to the Merger (as defined in Note 1), have been retroactively restated as shares reflecting the exchange ratio of approximately 0.703 established in the Merger as described in Note 1.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT) (Parenthetical) $ in Thousands	3 Months Ended	6 Months Ended
	Mar. 31, 2021 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2020 USD ($)
Statement of Stockholders' Equity [Abstract]
Private placement warrants acquired as part of the merger	$ 19,377	$ 19,377	$ 0
Share exchange ratio		0.703	0.703

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (52,968)	$ (30,005)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,254	1,725
Stock-based compensation	11,410	635
Change in right-of-use asset	1,047	1,075
Interest expense on notes and convertible debt	36	962
Amortization of debt issuance costs and debt discount	250	146
Change in fair value of warrant liabilities	14,898	115
Change in fair value of derivative liability	0	5,308
Inventory write down	144	1,767
Changes in operating assets and liabilities:
Accounts receivable	(2,344)	(210)
Inventory	(48)	(2,933)
Prepaid expenses and other assets	(37)	130
Accounts payable	(3,317)	(831)
Accrued and other liabilities	1,692	(2,173)
Operating lease liability	(1,363)	20
Net cash used in operating activities	(28,346)	(24,269)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment	(659)	(1,775)
Net cash used in investing activities	(659)	(1,775)
Net Cash Provided by (Used in) Financing Activities [Abstract]
Proceeds from the merger and private offering	291,454	0
Payment of offering costs	(27,124)	0
Repayment of debt	(7,000)	0
Proceeds from issuance of promissory notes to related parties	5,000	0
Repayment of promissory notes to related parties	(5,000)	0
Repurchase of common stock	(43)	0
Proceeds from exercise of stock options	504	2
Proceeds from issuance of Series B redeemable convertible preferred stock, net of issuance cost of $265	0	20,631
Net cash provided by financing activities	257,791	20,633
Net increase (decrease) in cash, cash equivalents and restricted cash	228,786	(5,411)
Cash, cash equivalents and restricted cash at beginning of period	12,642	18,405
Cash, cash equivalents and restricted cash at end of period	241,428	12,994
SUPPLEMENTAL DISCLOSURES OF OPERATING ACTIVITIES:
Cash paid for interest	635	567
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION:
Property and equipment purchases included in accounts payable and accrued liabilities	178	0
Private placement warrants acquired as part of the merger	19,377	0
Issuance of redeemable convertible preferred stock upon exercise of warrants	58,097	0
Conversion of redeemable convertible preferred stock to common stock	97,322	40,016
Right-of-use assets obtained in exchange for operating lease liability	0	6,409
Issuance of common stock pursuant to the conversion of convertible notes and accrued interest	0	73,003
Reclassification of common stock on exercise of stock options with notes receivable from stockholders	0	44
Warrants issued in connection with the closing of the Series B redeemable convertible preferred stock	0	691
Recognition of tranche right liability upon issuance	$ 0	$ 1,610

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) $ in Thousands	6 Months Ended
	Jun. 30, 2020 USD ($)
Statement of Cash Flows [Abstract]
Issuance cost	$ 265

Description of Business and Basis of Presentation	6 Months Ended
Description of Business and Basis of Presentation	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business and Basis of Presentation	Description of Business and Basis of Presentation Description of Business Ouster, Inc. was incorporated in the state of Delaware on June 4, 2020. The Company’s operating subsidiary, Ouster Technologies, Inc. (“OTI” and prior to the Merger (as defined below), named Ouster, Inc.), was incorporated in the state of Delaware on June 30, 2015. The Company is a leading provider of high-resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets, allowing each to understand and visualize the surrounding world and ultimately enabling safe operation and ubiquitous autonomy. Unless the context otherwise requires, references in this subsection to “the Company” refer to the business and operations of OTI (formerly known as Ouster, Inc.) and its consolidated subsidiaries prior to the Merger (as defined below) and to Ouster, Inc. (formerly known as Colonnade Acquisition Corp.) and its consolidated subsidiaries following the consummation of the Merger. Colonnade Acquisition Corp. (“CLA”), the Company’s predecessor, was originally a blank check company incorporated as a Cayman Islands exempted company on June 4, 2020. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. On March 11, 2021, CLA consummated a merger with the Company pursuant to an Agreement and Plan of Merger (the “Merger Agreement”) dated as of December 21, 2020, details of which are included below. Basis of Presentation and Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries (all of which are wholly owned) and have been prepared in conformity with U.S. generally accepted accounting principles (“US GAAP”) applicable to interim periods. The functional currency for the Company is the United States dollar. All intercompany balances and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements include all adjustments (consisting of only normal recurring adjustments) necessary for a fair statement of the results of operations for the periods shown. The unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements as of and for the year ended December 31, 2020 and the notes related thereto, included as Exhibit 99.1 to the Form 8-K filed with the Securities and Exchange Commission (“SEC”) on March 15, 2021, as amended on July 12, 2021. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by US GAAP. Certain information and note disclosures normally included in the audited financial statements prepared in accordance with US GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations. The results of operations for any interim period are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any other future years or interim periods. Impact of the COVID-19 Pandemic The Company has been actively monitoring the ongoing COVID-19 pandemic situation and its impact on the Company’s business. In response to the pandemic, numerous state and local jurisdictions have imposed “shelter-in-place” orders, quarantines and other restrictions. In the United States, governmental authorities have, at times, recommended, and in certain cases required, that elective, specialty and other procedures and appointments, be suspended or canceled. Similarly, in March and December 2020, the governor of California, where the Company’s headquarters are located, issued “stay at home” orders limiting non-essential activities, travel and business operations. Such orders or restrictions resulted in reduced operations at the Company’s headquarters (including its manufacturing facility), work stoppages, slowdowns and delays, travel restrictions and cancellation of events and have restricted the efforts of the Company’s sales representatives, thereby significantly and negatively impacting the Company’s operations. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19, including variants, the progression of vaccination roll-outs, and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. The situation surrounding COVID-19 remains fluid and the potential for a material impact on the Company increases the longer the virus impacts the level of economic activity in the United States and globally. Given the ongoing evolution of the COVID-19 and the global responses to curb its spread, the Company is not able to estimate the effects of the COVID-19 on its results of operations, financial condition, or liquidity for the year ending December 31, 2021 and beyond. Liquidity The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis. The Company has experienced recurring losses from operations, and negative cash flows from operations. As of June 30, 2021, the Company had an accumulated deficit of approximately $262.3 million. The Company has historically financed its operations primarily through the Merger and related transactions, the sale of convertible notes, equity securities, proceeds from debt and, to a lesser extent, cash received from sales. Management expects significant operating losses and negative cash flows from operations to continue for the foreseeable future. The Company expects to continue investing in product development and sales and marketing activities. The long-term continuation of the Company’s business plan is dependent upon the generation of sufficient revenues from its products to offset expenses. In the event that the Company does not generate sufficient cash flows from operations and is unable to obtain funding, the Company will be forced to delay, reduce, or eliminate some or all of its discretionary spending, which could adversely affect the Company’s business prospects, ability to meet long-term liquidity needs or ability to continue operations. The Company has concluded that its cash and cash equivalents as of June 30, 2021 are sufficient for the Company to continue as a going concern for at least one year from the date these unaudited condensed consolidated financial statements are available for issuance. Merger Agreement with Colonnade Acquisition Corp. and Beam Merger Sub, Inc. On December 21, 2020, OTI entered into the Merger Agreement with CLA and Beam Merger Sub, Inc. (“Merger Sub”), a Delaware corporation and subsidiary of CLA. OTI’s board of directors unanimously approved OTI’s entry into the Merger Agreement, and on March 11, 2021, the transactions contemplated by the Merger Agreement were consummated. Pursuant to the terms of the Merger Agreement, (i) CLA domesticated as a corporation incorporated under the laws of the State of Delaware and changed its name to “Ouster, Inc.” and (ii) Merger Sub merged with and into OTI (such transactions contemplated by the Merger Agreement, the “Merger”), with OTI surviving the Merger. As a result of the Merger, among other things, (1) each of the then issued and outstanding 5,000,000 CLA Class B ordinary shares, par value $0.0001 per share, of CLA (the “CLA Class B ordinary shares”) converted automatically, on a one-for-one basis, into a CLA Class A ordinary share (as defined below), (2) immediately following the conversion described in clause (1), each of the then issued and outstanding 25,000,000 Class A ordinary shares, par value $0.0001 per share, of CLA (the “CLA Class A ordinary shares”), converted automatically, on a one-for-one basis, into a share of common stock, par value $0.0001 per share, of Ouster (the “Ouster common stock”), (3) each of the then issued and outstanding 10,000,000 redeemable warrants of CLA (the “CLA warrants”) converted automatically into a redeemable warrant to purchase one share of Ouster common stock (the “Public warrants”) pursuant to the Warrant Agreement, dated August 20, 2020 (the “Warrant Agreement”), between CLA and Continental Stock Transfer & Trust Company (“Continental”), as warrant agent, and (4) each of the then issued and outstanding units of CLA that had not been previously separated into the underlying CLA Class A ordinary shares and underlying CLA warrants upon the request of the holder thereof (the “CLA units”), were cancelled and entitled the holder thereof to one share of Ouster common stock and one-half of one Public warrant, and (5) each of the then issued and outstanding 6,000,000 private placement warrants of CLA (the “Private Placement warrants”) converted automatically into a Public warrant pursuant to the Warrant Agreement. No fractional Public warrants were issued upon separation of the CLA units. Immediately prior to the effective time of the Merger, (1) each share of OTI’s Series B Preferred Stock, par value $0.00001 per share (the “OTI Preferred Stock”), converted into one share of common stock, par value $0.00001 per share, of OTI (the “OTI common stock” and, together with OTI Preferred Stock, the “OTI Capital Stock”) (such conversion, the “OTI Preferred Conversion”) and (2) all of the outstanding warrants to purchase shares of OTI Capital Stock were exercised in full or terminated in accordance with their respective terms (the “OTI Warrant Settlement”). As a result of and upon the closing of the Merger, among other things, all shares of OTI Capital Stock (after giving effect to the OTI Warrant Settlement) outstanding immediately prior to the closing of the Merger together with shares of OTI common stock reserved in respect of options to purchase shares of OTI common stock and restricted shares of OTI common stock (together, the “OTI Awards”) outstanding immediately prior to the closing of the Merger that were converted into awards based on Ouster common stock, were cancelled in exchange for the right to receive, or the reservation of, an aggregate of 150,000,000 shares of Ouster common stock (at a deemed value of $10.00 per share), which, in the case of OTI Awards, were shares underlying awards based on Ouster common stock, representing a fully-diluted pre-transaction. Upon closing of the Merger, the Company received gross proceeds of $299.9 million from the Merger and private offering, offset by $8.5 million of pre-merger costs relating to CLA and offerings costs of $26.6 million. The Merger was accounted for as a reverse recapitalization under US GAAP. Under this method of accounting, CLA is treated as the “acquired” company for financial reporting purposes. This determination is primarily based on OTI stockholders comprising a relative majority of the voting power of the Company and having the ability to nominate the members of the board of directors of the Company after the Merger, OTI’s operations prior to the Merger comprising the only ongoing operations of the Company following the Merger, and OTI’s senior management prior to the Merger comprising a majority of the senior management of the Company following the Merger. Accordingly, for accounting purposes, the financial statements of the Company represent a continuation of the financial statements of OTI with the Merger being treated as the equivalent of OTI issuing stock for the net assets of CLA, accompanied by a recapitalization whereby no goodwill or other intangible assets are recorded. Transactions and balances prior to the Merger are those of OTI. The shares and net loss per share available to holders of OTI’s common stock prior to the Merger have been retroactively restated as shares reflecting the exchange ratio established in the Merger Agreement. PIPE Investment On December 21, 2020, concurrently with the execution of the Merger Agreement, CLA entered into subscription agreements with certain institutional and accredited investors (collectively, the “PIPE Investors”), pursuant to which the PIPE Investors agreed to purchase, in the aggregate, 10,000,000 shares of Ouster common stock at $10.00 per share for an aggregate commitment amount of $100,000,000 (the “PIPE Investment”), a portion of which was funded by certain affiliates of Colonnade Sponsor LLC, CLA’s sponsor (the “Sponsor”). The PIPE Investment was consummated substantially concurrently with the closing of the Merger.

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2021

Accounting Policies [Abstract]

During the six months ended June 30, 2021, there were no significant changes to the Company’s significant accounting policies.

Recently Issued Accounting Pronouncements

Based on our public float as of June 30, 2021, we expect to become a large accelerated filer, and lose emerging growth company status, as of December 31, 2021. As of December 31, 2021, we will be required to adopt new or revised accounting standards when they are applicable to public companies that are not emerging growth companies.

In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326), to introduce a new impairment model for recognizing credit losses on financial instruments based on an estimate of current expected credit losses (“ECL”). Under the new model, an entity is required to estimate ECL on available-for-sale (AFS) debt securities only when the fair value is below the amortized cost of the asset and is no longer based on an impairment being “other-than-temporary”. The new model also requires the impairment calculation on an individual security level and requires an entity to use the present value of cash flows when estimating the ECL. The credit-related losses are required to be recognized through earnings and non-credit related losses are reported in other comprehensive income. The Company will adopt ASC 2016-13 for the December 31, 2021 annual period, with a modified retrospective application to all outstanding instruments and a cumulative effect adjustment recorded to opening retained earnings as of January 1, 2021. The Company does not believe the adoption of this new guidance will have a material impact on its consolidated financial statements.

In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, which aligns the requirements for capitalizing implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The Company will adopt ASC 2018-15 for the December 31, 2021 annual period. The Company does not believe the adoption of this new guidance will have a material impact on its consolidated financial statements.

In August 2020, the FASB issued ASU No. 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06). ASU 2020-06 simplifies the accounting for convertible debt and convertible preferred stock by removing the requirements to separately present certain conversion features in equity. In addition, the amendments in the ASU also simplify the guidance in ASC 815-40, Derivatives and Hedging: Contracts in Entity’s Own Equity, by removing certain criteria that must be satisfied in order to classify a contract as equity, which is expected to decrease the number of freestanding instruments and embedded derivatives accounted for as assets or liabilities. Finally, the amendments revise the guidance on calculating earnings per share, requiring use of the if-converted method for all convertible instruments and rescinding an entity’s ability to rebut the presumption of share settlement for instruments that may be settled in cash or other assets. The new standard is effective for the Company for annual periods beginning December 15, 2021. The Company is currently evaluating the impact of the adoption of this ASU on the Company’s condensed consolidated financial statements.

There have been no other newly issued or newly applicable accounting pronouncements that do not require adoption until a future date that have had, or are expected to have, a significant impact on the Company’s condensed consolidated financial statements.

Concentrations of credit risk

Financial instruments that potentially subject the Company to credit risk consist primarily of cash, cash equivalents, and restricted cash, and accounts receivable. Cash, cash equivalents and restricted cash are deposited with federally insured commercial banks in the United States and at times cash balances may be in excess of federal insurance limits. The Company generally does not require collateral or other security deposits for accounts receivable.

To reduce credit risk, the Company considers customer creditworthiness, past transaction history with the customer, current economic industry trends, and changes in customer payment terms when determining the collectability of specific customer accounts. Past due balances over 90 days and other higher risk amounts are reviewed individually for collectability. Based on management’s assessment, the Company provides for estimated uncollectible amounts through a charge to earnings and a credit to valuation allowance. Balances that remain outstanding after the Company has used reasonable collection efforts are written off through a charge to the valuation allowance and a credit to accounts receivable.

Accounts receivable from the Company’s major customers representing 10% or more of total accounts receivable was as follows:


	June 30, 2021	December 31, 2020
Customer A	*	13	%
Customer B	*	23	%

* Customer accounted for less than 10% of total accounts receivable in the period.

Revenue from the Company’s major customers representing 10% or more of total revenue was as follows:


	Three Months Ended June 30,			Six Months Ended June 30,
	2021	2020		2021		2020
Customer C	*	*		15	%	16	%
Customer D	*	45	%	*		30	%

* Customer accounted for less than 10% of total revenue in the period.

Concentrations of supplier risk

Purchases from the Company’s major suppliers representing 10% or more of total purchases were as follows:


	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020
Supplier A	12	%	15	%	*		*
Supplier B	14	%	16	%	15	%	14	%

* Supplier accounted for less than 10% of total purchases in the period.

Supplier B accounted for 38% and 23% of total accounts payable balance as of June 30, 2021 and December 31, 2020.

Fair Value of Financial Instruments

6 Months Ended

Jun. 30, 2021

Fair Value Disclosures [Abstract]

Fair Value of Financial Instruments

The Company applies the fair value measurement accounting standard whenever other accounting pronouncements require or permit fair value measurements. Fair value is defined in the accounting standard as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy is based on inputs to valuation techniques that are used to measure fair value that are either observable or unobservable. Observable inputs reflect assumptions market participants would use in pricing an asset or liability based on market data obtained from independent sources, while unobservable inputs reflect a reporting entity’s pricing based upon their own market assumptions. The fair value hierarchy consists of the following three levels:

•Level 1 - Quoted prices for identical instruments in active markets.

•Level 2 - Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.

•Level 3 - Instruments whose significant value drivers are unobservable.

On June 30, 2021, the Company’s Level 3 liabilities consisted of the Private Placement warrant liability. The determination of the fair value of warrant liability is discussed in Note 6.

On December 31, 2020, the Company’s Level 3 liabilities consisted of the redeemable convertible preferred stock warrant liability. The determination of the fair value of warrant liability is discussed in Note 6.

The following table provides information by level for the Company’s assets and liabilities that were measured at fair value on a recurring basis (in thousands):


	June 30, 2021
	Level 1		Level 2		Level 3		Total
Assets
Money market funds	$	238,855	$	—	$	—	$	238,855
Total financial assets	$	238,855	$	—	$	—	$	238,855
Liabilities
Warrant liabilities	$	—	$	—	$	25,471	$	25,471
Total financial liabilities	$	—	$	—	$	25,471	$	25,471


	December 31, 2020
	Level 1		Level 2		Level 3		Total
Assets
Money market funds	$	10,493	$	—	$	—	$	10,493
Total financial assets	$	10,493	$	—	$	—	$	10,493
Liabilities
Warrant liabilities	$	—	$	—	$	49,293	$	49,293
Total financial liabilities	$	—	$	—	$	49,293	$	49,293

Money market funds are included within Level 1 of the fair value hierarchy because they are valued using quoted market prices.

The fair value of the redeemable convertible preferred stock warrant, redeemable convertible preferred stock tranche and Private Placement warrant liabilities is based on significant unobservable inputs, which represent Level 3 measurements within the fair value hierarchy. In determining the fair value of the warrant liabilities, the Company used the Black-Scholes option pricing model to estimate the fair value using unobservable inputs including the expected term, expected volatility, risk-free interest rate and dividend yield (see Note 6).

The following table presents a summary of the changes in the fair value of the Company’s Level 3 financial instruments (in thousands):


	Redeemable Convertible Preferred Stock Warrant Liability		Redeemable Convertible Preferred Stock Tranche Liability		Private Placement Warrant Liability		Derivative Liability
Fair value as of January 1, 2020	$	(162)	$	—	$	—	$	—
Change in the fair value included in other income (expense), net	(115)		—		—		(5,308)
Recognition of preferred stock warrant and tranche liability upon issuance	(691)		(1,610)		—		—
Extinguishment of derivative liability upon conversion of convertible notes	—		—		—		5,308
Fair value as of June 30, 2020	$	(968)	$	(1,610)	$	—	$	—

Fair value as of January 1, 2021	(49,293)		—		—		—
Private placement warrant liability acquired as part of the Merger	—		—		(19,377)		—
Change in the fair value included in other income (expense), net	(8,804)		—		(6,094)		—
Issuance of preferred stock upon exercise of warrants	58,097		—		—		—
Fair value as of June 30, 2021	$	—	$	—	$	(25,471)	$	—

Disclosure of Fair Values

Our financial instruments that are not re-measured at fair value include accounts receivable, accounts payable, accrued and other current liabilities, convertible notes and debt. The carrying values of these financial instruments approximate their fair values.

Organization, Consolidation and Presentation of Financial Statements [Abstract]

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Balance Sheet Components

6 Months Ended

Jun. 30, 2021

Balance Sheet Components

Cash and Cash Equivalents

The Company’s cash and cash equivalents consist of the following (in thousands):


	June 30, 2021		December 31, 2020
Cash	$	1,293	$	869
Cash equivalents:
Money market funds(1)	238,855		10,493

Total cash and cash equivalents	$	240,148	$	11,362

(1)The Company maintains a cash sweep account which is included in money market funds as of June 30, 2021. Cash is invested in the short-term money market funds, which is a cash sweep for uninvited cash that earns interest.

Restricted Cash

Restricted cash consists of certificates of deposit held by a bank as security for outstanding letters of credit. The Company had a restricted cash balance of $1.3 million and $1.3 million as of June 30, 2021 and December 31, 2020, respectively, which has been excluded from the Company’s cash and cash equivalents balances. The Company presented $0.3 million of the total amount of restricted cash within current assets on the condensed consolidated balance sheets as of June 30, 2021 and December 31, 2020. The remaining restricted cash balance of $1.0 million and $1.0 million is included in non-current assets on the condensed consolidated balance sheets as of June 30, 2021 and December 31, 2020, respectively.

Reconciliation of cash, cash equivalents and restricted cash as shown in the condensed consolidated statement of cash flows to the respective accounts within the condensed consolidated balance sheet is as follows (in thousands):


	June 30, 2021		June 30, 2020
Cash and cash equivalents	$	240,148	$	11,438
Restricted cash, current	276		276
Restricted cash, non-current	1,004		1,280
Total cash, cash equivalents and restricted cash	$	241,428	$	12,994

Inventory

Inventory, consisting of material, direct and indirect labor, and manufacturing overhead, consists of the following (in thousands):


	June 30, 2021		December 31, 2020
Raw materials	$	1,887	$	1,376
Work in process	1,360		1,249
Finished goods	1,474		2,192
Total inventory	$	4,721	$	4,817

Total inventory balance as of June 30, 2021 and December 31, 2020 includes a write down of $2.1 million and $2.7 million, respectively, for obsolete, scrap, or returned inventory. During the three months ended June 30, 2021 and 2020, $0.1 million and $0.1 million of inventory write offs were charged to cost of revenue. During the six months ended June 30, 2021 and 2020, respectively, $0.1 million and $1.8 million of inventory write offs were charged to cost of revenue.

Prepaid expenses and other current assets

Prepaid expenses and other current assets consist of the following (in thousands):


	June 30, 2021		December 31, 2020
Prepaid insurance	$	3,281	$	206
Prepaid expenses	1,832		694
Receivable from contract manufacturer	43		1,521
Security deposit	1,211		20
Total prepaid and other current assets	$	6,367	$	2,441

Accrued and Other Current Liabilities

Accrued and other current liabilities consist of the following (in thousands):


	June 30, 2021		December 31, 2020
Customer deposits	48		71
Accrued compensation	2,478		1,618
Uninvoiced receipts	2,777		1,947
Other	956		485
Total accrued and other current liabilities	$	6,259	$	4,121

Debt	6 Months Ended
Debt	Jun. 30, 2021
Debt Disclosure [Abstract]
Debt	Debt Runway Growth Loan Agreement On November 27, 2018, the Company entered into a Loan and Security Agreement with Runway Growth Credit Fund Inc. (“Runway Loan and Security Agreement”). The Runway Loan and Security Agreement provided for loans in an aggregate principal amount up to $10.0 million with a loan maturity date of November 15, 2021. The loan carried an interest rate equal to LIBOR plus 8.5%, unless LIBOR becomes no longer attainable or ceases to fairly reflect the costs of the lender, in which case the applicable interest rate shall be Prime Rate plus 6.0%. In an event of default, annual interest is increased by 5.0% above the otherwise applicable rate. The loan’s annual effective interest rate was approximately 16.4% for each of the six months ended June 30, 2021 and 2020. In conjunction with the Runway Loan and Security Agreement, the Company issued a warrant to purchase 35,348 shares of Series A redeemable convertible preferred stock (the “Series A Preferred Stock”) of the Company (4.0% of original principal amount of $10.0 million, divided by the exercise price), with an exercise price of $11.3518 per share. The fair value of this warrant was estimated to be $0.1 million and accounted for as a debt discount. On August 5, 2019, in connection with the second amendment to the Runway Loan and Security Agreement, the Company amended the warrant issued to Runway Growth to increase the number of shares available to purchase to 53,023 shares of Series A Preferred Stock of the Company. The aggregate value of the warrants increased by $0.1 million after the warrant modification. The warrants were exercised on March 11, 2021 and the warrant liability was remeasured to fair value with the increase recognized as a loss of $0.6 million for the three and six months ended June 30, 2021 within other income (expense), net in the consolidated statements of operations and comprehensive loss. The warrant liability was remeasured to fair value as of June 30, 2020 and the reduction was recognized as a gain of $0.2 million. On March 26, 2021 the Company terminated the Runway Loan and Security Agreement and repaid the $7.0 million principal amount outstanding as well as interest and fees amounting to $0.4 million. The Company incurred no prepayment fees in connection with the termination and all liens and security interests securing the loan made pursuant to the Runway Loan and Security Agreement were released upon termination. As of June 30, 2021 and December 31, 2020, the outstanding principal balance of the loan was nil and $7.0 million, respectively. Promissory notes The Company issued a $5 million promissory note in January 2021 to certain current investors of the Company (or their respective affiliates) to help continue to fund the Company’s ongoing operations through the consummation of the Merger. The note accrued interest at a rate equal to LIBOR plus 8.5% per annum and was repaid on March 11, 2021 in accordance with its terms in connection with the consummation of the Merger

Warrants

6 Months Ended

Jun. 30, 2021

Warrants

Series A and B Redeemable Convertible Preferred Stock Warrants and Tranche Liability

On November 27, 2018, in connection with the execution of the Runway Loan and Security Agreement, OTI issued a warrant to purchase 35,348 shares of Series A Preferred Stock of OTI at an exercise price of $11.3518 per share (the “Runway warrant”). On August 5, 2019, in connection with the second amendment to the Runway Loan and Security Agreement, OTI amended the Runway warrant to increase the number of shares available to purchase to 53,023 shares of Series A Preferred Stock of OTI at an exercise price of $11.3518 per share.

The Runway warrants included a cashless exercise provision under which their holders could, in lieu of payment of the exercise price in cash, surrender the Runway warrant and receive a net amount of shares based on the fair market value of OTI’s stock at the time of exercise of the warrants after deduction of the aggregate exercise price. The Runway warrants contained provisions for adjustment of the exercise price and number of shares issuable upon the exercise of the Runway warrants in the event of certain stock dividends, stock splits, reorganizations, reclassifications, and consolidations.

The fair value of the warrants issued was recorded as of the date of initial issuance in the amount of $0.1 million. The subsequent issuance of warrants pursuant to the August 5, 2019 amendment to the Runway Loan and Security Agreement was recorded in the amount of $0.1 million. Immediately prior to the Merger, the warrants were exercised in full in accordance with their terms.

On April 3, 2020, in connection with the closing of the Series B redeemable convertible preferred stock, OTI issued a warrant to purchase 4,513,993 shares of Series B redeemable convertible preferred stock of the Company at an exercise price of

$0.3323 per share (the “Series B warrants”). The Series B warrants could be exercised prior to the earliest to occur of (i) the 10 year anniversary of the date of issuance, (ii) the consummation of a liquidation transaction, or (iii) the consummation of an initial public offering. The Series B warrants included a cashless exercise provision under which their holders may, in lieu of payment of the exercise price in cash, surrender the warrant and receive a net amount of shares based on the fair market value of the Company’s stock at the time of exercise of the warrants after deduction of the aggregate exercise price. The Series B warrants contained provisions for adjustment of the exercise price and number of shares issuable upon the exercise of the Series B warrants in the event of certain stock dividends, stock splits, reorganizations, reclassifications, and consolidations.

The Series B warrants were initially recognized as a liability at a fair value of $0.7 million. The Series B warrants were exercised on February 11, 2021 and the warrant liability was remeasured to fair value as of that date, resulting in a loss of $8.3 million for the six months ended June 30, 2021, classified within other income (expense), net in the consolidated statements of operations and comprehensive loss. Upon exercise redeemable convertible preferred stock converted into common stock pursuant to the conversion rate effective immediately prior to the Merger.

Historically, value was assigned to each class of equity securities using an option pricing model method (“OPM”). In September 2020, OTI began allocating the equity value using a hybrid method that utilizes a combination of the OPM and the probability weighted expected return method (“PWERM”). The PWERM is a scenario-based methodology that estimates the fair value of equity securities based upon an analysis of future values for OTI, assuming various outcomes. As the probability of a transaction with a special purpose acquisition company (“SPAC”) increased, the fair value of the redeemable convertible preferred stock warrant liability increased as of the date of the exercise.

The redeemable convertible preferred stock warrants were valued using the following assumptions under the Black-Scholes option-pricing model:


	Initial Issuance Date			Subsequent Issuance Date			December 31, 2020			February 11, 2021			March 11, 2021
Stock price	$	5.80		$	5.80		$	7.11		$	10.27		$	8.44
Expected term (years)	10.00			9.31			2.00			2.00			2.00
Expected volatility	57.81		%	57.35		%	76.00		%	76.00		%	76.00		%
Risk-free interest rate	3.06		%	1.75		%	0.13		%	0.13		%	0.13		%
Dividend yield	0		%	0		%	0		%	0		%	0		%

Series B Redeemable Convertible Preferred Stock Tranche

In April 2020 and May 2020, the Company issued 62,505,102 shares of Series B redeemable convertible preferred stock at $0.3323 per share. For each share purchased, the purchaser had an option to purchase an additional share of Series B redeemable convertible preferred stock at $0.3323 per share, exercisable at any time prior to August 13, 2020 (the “Tranche Right”). The Company determined that the Tranche Right represented a freestanding obligation of the Company to issue additional shares of contingently redeemable shares if exercised by the holder. The freestanding redeemable convertible preferred stock tranche liability was initially recorded at fair value, with fair value changes recorded within other income (expense), net in the consolidated statements of operations and comprehensive loss.

Private Placement Warrants

Simultaneously with the closing of the Company’s initial public offering (the “IPO”) in August 2020, the sponsor of CLA, Colonnade Sponsor LLC, purchased an aggregate of 6,000,000 Private Placement warrants at a price of $1.00 per warrant, for an aggregate purchase price of $6,000,000. The Private Placement warrants will become exercisable 12 months following the closing of the Company’s IPO, and will expire five years from the completion of the Merger, or earlier upon redemption or liquidation. Each Private Placement warrant will be exercisable for one Class A ordinary share at a price of $11.50 per share. On March 11, 2021, each outstanding Private Placement warrant automatically converted into a warrant to purchase one share of Ouster common stock pursuant to the Warrant Agreement.

The Private Placement warrants were initially recognized as a liability at a fair value of $19.4 million and the Private Placement warrant liability was remeasured to fair value as of March 31, 2021 and June 30, 2021, resulting in a gain of $4.6 million and $6.1 million for the three and six months ended June 30, 2021, classified within other income (expense), net in the condensed consolidated statements of operations and comprehensive loss.

The Private Placement warrants were valued using the following assumptions under the Black-Scholes option-pricing model:


	March 11, 2021			March 31, 2021			June 30, 2021
Stock price	$	12.00		$	8.50		$	12.49
Exercise price of warrant	11.5			11.5			11.5
Expected term (years)	5.00			4.95			4.7
Expected volatility	27.00		%	43.00		%	43.00		%
Risk-free interest rate	0.78		%	0.92		%	0.92		%

Public Warrants

The Company, in its IPO in August 2020, issued 20,000,000 units that each consisted of one Class A ordinary share and one half warrant to purchase a Class A ordinary share, which we refer to as CLA warrants before the Merger and Public warrants after the Merger. These warrants may only be exercised for a whole number of shares, and no fractional warrants were issued or issuable upon separation of the units and only whole warrants will trade. The warrants will become exercisable 12 months following the closing of the Company’s IPO, and will expire five years from the completion of the Merger, or earlier upon redemption or liquidation. Each Public warrant will be exercisable at a price of $11.50 per share. On March 11, 2021, upon the closing of the Merger pursuant to the Merger Agreement (Note 1), each of the 9,999,996 outstanding warrants, as adjusted for any fractional warrants that were not issued upon separation, was converted automatically into a redeemable Public warrant to purchase one share of the Company’s common stock. The Public warrants were recognized as equity upon the Merger in the amount of $17.9 million.

Once the Public warrants become exercisable and prior to their expiration, the Company may redeem the Public warrants at a price of $0.01 per warrant, provided that the closing price of the Company’s common stock equals or exceeds $18.00 per share for any 20 trading days within a 30 trading-day period ending on the third trading day prior to the date on which the Company gives proper notice of such redemption to the warrants holders.

Commitments and Contingencies	6 Months Ended
Commitments and Contingencies	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Letters of credit In connection with two leases, the Company obtained two letters of credit from a bank as required by the lease agreements. If the Company defaults under the terms of the applicable lease, the lessor will be entitled to draw upon the letters of credit in the amount necessary to cure the default. The amounts covered by the letters of credit are collateralized by certificates of deposit, which are included in restricted cash on the condensed consolidated balance sheets as of June 30, 2021 and December 31, 2020. The outstanding amount of the letters of credit was $1.3 million as of June 30, 2021 and December 31, 2020. Non-cancelable purchase commitments As of June 30, 2021, the Company had non-cancelable purchase commitments to a third-party contract manufacturer for approximately $5.7 million and other vendors for approximately $6.2 million. Litigation The Company is involved in various legal proceedings arising in the ordinary course of business. The Company accrues a liability when a loss is considered probable and the amount can be reasonably estimated. When a material loss contingency is reasonably possible but not probable, the Company does not record a liability, but instead discloses the nature and the amount of the claim, and an estimate of the loss or range of loss, if such an estimate can be made. Legal fees are expensed as incurred. Based on the opinion of legal counsel and other factors, management believes that the final disposition of these existing matters will not have a material adverse effect on the business, results of operations, financial condition, or cash flows of the Company. The Company has identified certain claims as a result of which a loss may be incurred, but in the aggregate the loss is expected to be insignificant. This assessment is based on our current understanding of relevant facts and circumstances. As such, our view of these matters is subject to inherent uncertainties and may change in the future. Significant judgment is required in both the determination of probability and the determination as to whether an exposure is reasonably estimable. Actual outcomes of these legal and regulatory proceedings may materially differ from our current estimates. For other claims regarding proceedings that are in an initial phase, the Company is unable to estimate the range of possible loss, if any, but at this time believes that any loss related to such claims will not be material. As of June 30, 2021 and December 31, 2020 there are no material litigation matters. Indemnification From time to time, the Company enters into agreements in the ordinary course of business that include indemnification provisions. Generally, in these provisions the Company agrees to defend, indemnify, and hold harmless the indemnified parties for claims and losses suffered or incurred by such indemnified parties for which the Company is responsible under the applicable indemnification provisions. The terms of the indemnification provisions vary depending upon negotiations between the Company and its counterpart; however, typically, these indemnification obligations survive the term of the contract and the maximum potential amount of future payments the Company could be required to make pursuant to these provisions are uncapped. To date, the Company has never incurred costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnity agreements pursuant to which it has indemnified its directors and officers, to the extent legally permissible, against all liabilities reasonably incurred in connection with any action in which such individual may be involved by reason of such individual being or having been a director or executive officer, other than liabilities arising from willful misconduct of the individual. To date, the Company has never incurred costs to defend lawsuits or settle claims related to these indemnity agreements. The unaudited condensed consolidated financial statements do not include a liability for any potential obligations under the indemnification agreements at June 30, 2021 and December 31, 2020.

Redeemable Convertible Preferred and Common Stock

6 Months Ended

Jun. 30, 2021

Redeemable Convertible Preferred and Common Stock

The Company’s common stock and warrants trade on the New York Stock Exchange under the symbol “OUST” and “OUSTWS”, respectively. Pursuant to the terms of the Second Amended and Restated Certificate of Incorporation, the Company is authorized and has available for issuance the following shares and classes of capital stock, each with a par value of $0.0001 per share: (i) 1,000,000,000 shares of common stock; (ii) 100,000,000 shares of preferred stock. Immediately following the Merger, there were 161,449,205 shares of common stock with a par value of $0.0001, and 15,999,996 warrants outstanding. The holder of each share of common stock is entitled to one vote.

The Company has retroactively adjusted the shares issued and outstanding prior to March 11, 2021 to give effect to the exchange ratio established in the Merger Agreement to determine the number of shares of common stock into which they were converted.

Immediately prior to the Merger, OTI’s certificate of incorporation, as amended, authorized it to issue 342,367,887 shares of $0.00001 par value, with 210,956,516 shares designated as common stock and 131,411,372 shares of redeemable convertible preferred stock.

Series Seed Financing and conversion

In April 2016, OTI issued 1,887,253 shares of Series Seed redeemable convertible preferred stock at $1.02 per share for net proceeds of $1.8 million, net of $0.1 million stock issuance costs. In April 2016, OTI issued 44,256 shares to an investor upon conversion of a note having a balance of principal and interest of $45,000. In May 2016, OTI issued 563,725 shares of Series Seed redeemable convertible preferred stock at $1.02 per share for net proceeds of $0.6 million. In July 2016, OTI issued 445,942 shares of Series Seed redeemable convertible preferred stock at $1.02 per share for net proceeds of $0.5 million.

In April 2020, in order to induce the closing of the Series B Financing, the holders exercised the embedded conversion feature and all the outstanding Series Seed redeemable convertible preferred stock shares were converted to 2,941,176 shares of OTI’s common stock.

Series A Financing and conversion

In October 2017, OTI issued 1,324,511 shares of Series A Preferred Stock at $11.3158 per share for net proceeds of $14.8 million, net of $0.2 million of stock issuance costs. In October 2017, OTI issued 1,253,556 shares of Series A Preferred Stock upon conversion of multiple notes having a principal and interest balance of $4.6 million. In December 2017, OTI issued 715,712 shares of Series A Preferred Stock at $11.3158 per share for net proceeds of $8.1 million.

In April 2020, in order to induce the closing of the Series B Financing, the holders exercised the embedded conversion feature and all of the outstanding Series A redeemable convertible preferred stock shares were converted to 3,293,779 shares of OTI’s common stock.

Series B Financing

In April 2020, OTI issued 45,185,071 shares of Series B redeemable convertible preferred stock at $0.3323 per share for net proceeds of $15.1 million, less $0.1 million of stock issuance costs. In May 2020, OTI issued 17,320,031 shares of Series B redeemable convertible preferred stock at $0.3323 per share for net proceeds of $5.8 million, less $0.1 million of stock issuance costs. In July 2020, OTI issued 37,970,846 shares of Series B redeemable convertible preferred stock at $0.3323 per share for net proceeds of $12.5 million, less $0.1 million of stock issuance costs. In August 2020, OTI issued 25,286,587 shares of Series B redeemable convertible preferred stock at $0.3323 per share for net proceeds of $8.4 million, less $0.1 million of stock issuance costs.

On March 11, 2021, upon the closing of the Transaction pursuant to the Merger Agreement (Note 1), all of the outstanding redeemable convertible preferred stock was converted to the Company’s common stock pursuant to the conversion rate effective immediately prior to the Transaction and the remaining amount was reclassified to additional paid-in capital. As of June 30, 2021, the Company does not have any redeemable convertible preferred stock outstanding.

Prior to the Merger, redeemable convertible preferred stock as of December 31, 2020, consisted of the following (in thousands, except share and per share data):


	December 31, 2020
Series	Issue Price per share		Shares Authorized	Shares Issued and Outstanding	Liquidation Amount		Carrying Amount
Series B	$	0.33	131,411,372	88,434,754	$	41,791	$	39,225

Prior to the Merger, the significant features of OTI’s redeemable convertible preferred stock were as follows:

Dividend provisions

The Series Seed, Series A and Series B preferred stockholders are entitled to receive dividends prior and in preference to any dividends on the common stock, at a rate of $0.0612, $0.6789 and $0.019938 per share, respectively, per annum on a non-cumulative basis, when and if declared by the board of directors, subject to the prior rights of the preferred stockholders. After payment of such dividend, any additional dividends would be distributed among the holders of the preferred stock and common stock pro rata based on the number of shares of common stock then held by each holder (assuming conversion of all shares of preferred stock into common stock).

Liquidation preference

In the event of liquidation, dissolution or winding up of the Company, merger or a reduction of capital through the sale or lease of all or substantial part of the business of the Company, before any distribution or payment were to be made to the holders of common stock, the holders of Series Seed, Series A and Series B redeemable convertible preferred stock were entitled to receive $1.02, $11.3518 and $0.3323 per share (subject to adjustment in the event of any share dividend, share split, combination, or other recapitalization), respectively, plus any declared but unpaid dividends on such shares. If the assets and funds were insufficient for such distribution, they were entitled to receive a pro rata distribution, based on the relative preferred stock ownership and in proportion to the preferential amount each such holder is otherwise entitled. If the assets and funds are in excess of amounts distributed to the preferred stockholders, the remaining assets and funds shall be distributed pro rata to the holders of the common stock. If the holders of the redeemable convertible preferred stock would receive a greater distribution if they converted to common stock, then such conversion would have been assumed prior to distribution.

Conversion rights

The holders of Series Seed, Series A and Series B redeemable convertible preferred stock had a right to convert their stock into nonassessable shares of common stock at a conversion rate equal to their respective liquidation preferences divided by a conversion price of $1.02, $11.3518 and $0.3323, respectively, which was adjusted for any stock splits, stock dividends, combination, subdivisions, recapitalizations or similar transactions. On March 11, 2021, upon the closing of the Transaction pursuant to the Merger Agreement (Note 1), all of the outstanding redeemable convertible preferred stock was converted to the Company’s common stock pursuant to the conversion rate effective immediately prior to the Transaction and the remaining amount was reclassified to additional paid-in capital.

Redemption rights

The redeemable convertible preferred stock were recorded in mezzanine equity because while it was not currently redeemable, it could become redeemable at the option of the preferred stockholders upon the occurrence of certain deemed liquidation events that were considered not solely within the Company’s control for an amount equal to the shares respective liquidation preference plus declared and unpaid dividends.

Voting rights

Each holder of redeemable convertible preferred stock was entitled to the number of votes equal to the number of shares of common stock into which such redeemable convertible preferred stock could then be converted and, with respect to such vote, holders of redeemable convertible preferred stock were entitled to vote together with the holders of common stock as a single class on all matters.

Stock-based compensation

6 Months Ended

Jun. 30, 2021

Share-based Payment Arrangement [Abstract]

Stock-based compensation

We currently have two equity incentive plans, our 2015 Stock Plan (the “2015 Plan”) and our 2021 Incentive Award Plan (the “2021 Plan”). As of March 11, 2021, we no longer grant equity awards pursuant to our 2015 Plan, but it continues to govern the terms of outstanding stock options that were granted prior to that date.

On October 12, 2020, the Company issued $1.1 million partial recourse promissory notes to certain executives and employees. The promissory notes carried 0.38% annual cash interest and were due on earliest of 9th anniversary of the date of issuance of the notes, or termination of employment of the executive/employee, or filing by the Company of a registration statement under the Securities Act of 1933, or promissory notes being prohibited under Section 13(k) of the Securities Exchange Act of 1934 or closing of change a in control of the Company. At issuance, the promissory notes were used to settle certain executives’ and employees’ obligations for 2,883,672 vested and 4,603,833 unvested ISOs that were exercised and no cash was exchanged. In March 2021, in connection with the close of the Merger, the Company forgave half of the respective obligations under the promissory notes for certain executives and required such noteholders to repay the remaining balance of $0.3 million under each of their respective notes. Additional compensation expense of $0.3 million was recognized in general and administrative expenses in the three months ended March 31, 2021 and the six months ended June 30, 2021 for the value of the loans forgiven. Obligations under the promissory notes for non-executive noteholders of $0.5 million is outstanding as of June 30, 2021.

2021 Incentive Award Plan

On March 11, 2021, the Board of Directors approved the 2021 Plan. The 2021 Plan provides for the grant of stock options, stock appreciation rights, restricted stock units, performance stock unit awards and other forms of equity compensation (collectively, “equity awards”). In addition, the 2021 Plan provides for the grant of performance bonus awards. All awards within the 2021 Plan may be granted to employees, including officers, as well as directors and consultants, within the limit defined in the 2021 Plan. 18,558,576 shares of the Company’s common stock have been initially reserved for issuance under the 2021 Plan. The 2021 Plan includes an evergreen provision that provides for an annual increase in the number of shares of common stock available for issuance thereunder beginning on January 1, 2022 and ending on January 1, 2031, equal to 5% of the shares of Company common stock outstanding on the last day of the immediately preceding fiscal year and such smaller number of shares as determined by the Board of Directors or a committee thereof. As of June 30, 2021, the Company had 15,503,561 shares of common stock available pursuant to new awards under the 2021 Plan.

Options and stock appreciation rights under the 2021 Plan will be exercisable at such times and as specified in the Award Agreement (as defined in the 2021 Plan) provided that the term of an option or stock appreciation will not exceed ten years. Options granted under the 2021 Plan may be Incentive Stock Options (ISOs) or Non-statutory Stock Options, as determined by the Administrator at the time of grant of an option and subject to the applicable provisions of Section 422 of the Internal Revenue Code and the regulations promulgated thereunder. The exercise price of an option will be no less than 100% of the fair

market value of the shares of common stock on the date of grant. The exercise price of an ISO granted to a 10% shareholder will be no less than 110% of the fair market value of the shares on the date of grant and the term of the ISO will not exceed five years. The Company granted an option to purchase 1,614,492 shares of Company common stock to a senior advisor serving on the Company’s board of directors as chair with 20% of the total number of such option shares vesting on each of the first five anniversaries from the senior advisor’s employment start date, subject to his continued employment with the Company and provided that option grant will only be exercisable in the event that the closing trading price per share of the Company stock equals or exceeds 130% of the exercise price per share of the option for 30 consecutive trading days. The senior advisor has resigned in June 2021 and the option to purchase 1,614,492 shares of Company common stock was forfeited.

Restricted stock and restricted stock units granted to employees generally vest as to 25% of the shares on the first anniversary service date of the grant, and quarterly thereafter so as to be 100% vested on the fourth anniversary of the vesting commencement date. All participants holding shares of restricted stock will be entitled to all the rights of a stockholder with respect to such shares and have voting power and other rights with respect to such shares, provided, however, that such shares are held in escrow and subject to forfeiture until the shares vested. The Company granted 807,246 restricted stock units to a senior advisor who serves as chair of the board of directors with vesting of 20% of the total number of restricted stock units on each of the first five anniversaries from the employment start date, subject to continued employment with the Company. The senior advisor has resigned in June 2021 and all restricted stock unit awards granted were forfeited.

In March 2021, the Company also granted 152,628 restricted stock units to several members of the board of directors subject to standard terms of these awards.

Vesting schedules for performance stock unit awards and other equity awards vary and are linked to one or more of performance or other specific criteria, including service to the Company, determined to be appropriate by the Board, in each case on a specified date or dates or over any period or periods determined by the Board. The performance condition awards are automatically forfeited in their entirety, without any cost to or action by the Company, if there has been no achievement of the performance condition. The Company granted 807,246 performance stock units to a senior advisor who serves as chair of the board of directors with vesting earned over four years based on achieving increases in the Company’s stock price from the date of grant ranging from 150%, to earn 25% of the performance stock units, to 300% to earn the entire award of performance stock units. Each performance stock unit constitutes the right to receive one share of Company common stock upon vesting. As noted above, the senior advisor has resigned in June 2021 and all performance stock unit awards granted were forfeited.

Performance bonus awards are denominated in cash, stock or a combination thereof, and shall be payable upon the attainment of performance goals that are established by the Board and relate to one or more of performance or other specific criteria, including service to the Company, in each case on a specified date or dates or over any period or periods determined by the Board.

Stock option activity for the six months ended June 30, 2021 is as follows:


	Number of Shares Underlying Outstanding Options	Weighted- Average Exercise Price per Share		Weighted- Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Outstanding—December 31, 2020	25,732,503	$	0.39	9.60	$	245,746
Options granted	645,796	10.26		9.80	$	1,440
Options exercised	(727,116)	0.13		9.00	$	6,083
Options cancelled	(432,918)	0.15
Outstanding—June 30, 2021	25,218,265	$	0.66	9.10	$	298,358
Vested and expected to vest—June 30, 2021	25,218,265	$	0.66	9.10	$	298,358
Exercisable—June 30, 2021	7,406,315	$	0.29	9.00	$	90,358

The following table summarizes the weighted-average assumptions used in estimating the fair value of options granted in the six months ended June 30, 2021, using the Black-Scholes option-pricing model:


	Six Months Ended
	June 30, 2020
Expected term (years)	6.00
Expected volatility	63.19	%
Risk-free interest rate	1.03	%
Expected dividend rate	—	%

The following table summarizes information about stock options outstanding and exercisable at June 30, 2021.


		Options Outstanding				Options Exercisable
Exercise Price		Options Outstanding	Weighted Average Remaining Contractual Life (Years)	Weighted Average Exercise Price		Options Exercisable	Weighted Average Remaining Contractual Life (Years)	Weighted Average Exercise Price
$	0.13	6,548,017	8.90	$	0.13	3,569,978	8.88	$	0.13
$	0.15	10,455,884	9.21	$	0.15	2,537,865	9.08	$	0.15
$	0.26	35,159	0.45	$	0.26	35,159	0.45	$	0.26
$	1.00	7,524,116	9.25	$	1.00	1,254,019	9.25	$	1.00
$	3.92	7,976	0.45	$	3.92	7,976	0.45	$	3.92
$	5.80	1,318	0.45	$	5.80	1,318	0.45	$	5.80
$	10.26	645,796	9.78	$	10.26	—		$	—
		25,218,266				7,406,315

The weighted average grant date fair value of options granted during the six months ended June 30, 2021 was $5.9.

As of June 30, 2021, there was approximately $30.0 million of unamortized stock-based compensation expense related to unvested stock options that is expected to be recognized over a weighted average period of 1.8 years.

Restricted Stock Awards (“RSA”)

A summary of RSA activity under the 2015 Plan is as follows:


	Number of Shares	Weighted Average Grant Date Fair Value (per share)
Unvested – December 31, 2020	40,754	$	0.67
Granted during the period	—	—
Canceled during the period	—	—
Vested during the period	(11,644)	0.67
Unvested — June 30, 2021	29,110	$	0.67

The weighted-average estimated fair value of RSAs granted in the six months ended June 30, 2021 was Nil per share. The total fair value of RSAs vested during the six months ended June 30, 2021 was less than $0.1 million.

Restricted Stock Units (“RSU”)

A summary of RSU activity is as follows:


	Number of Shares	Weighted Average Grant Date Fair Value (per share)
Unvested – December 31, 2020	—	$	—
Granted during the period	2,616,948	10.01
Canceled during the period	—	—
Vested during the period	(28,319)	11.52
Unvested — June 30, 2021	2,588,629	$	9.99

Stock compensation expense is recognized on a straight-line basis over the vesting period of each RSU. As of June 30, 2020, total compensation expense related to unvested RSUs granted to employees, but not yet recognized, was $22.1 million, with a weighted-average remaining vesting period of 3.2 years.

The Company recognized stock-based compensation for all stock options in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020
Cost of revenue	$	133	$	59	$	251	$	101
Research and development	1,321		152		2,242		287
Sales and marketing	719		39		985		89
General and administrative	3,981		210		7,932		158
Total stock-based compensation	$	6,154	$	460	$	11,410	$	635

Net Loss Per Common Share

6 Months Ended

Jun. 30, 2021

Earnings Per Share [Abstract]

Net Loss Per Common Share

The following table sets forth the computation of basic and diluted net loss per common share attributable to common stockholders (in thousands, except share and per share data):


	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020
Numerator:
Net loss	$	(32,011)	$	(11,312)	$	(52,968)	$	(30,005)
Denominator:
Weighted average shares used to compute basic and diluted net loss per share	155,923,689		19,138,365		106,070,590		13,452,766
Net loss per common share—basic and diluted	$	(0.21)	$	(0.59)	$	(0.50)	$	(2.23)

The shares and net loss per common share, prior to the Merger, have been retroactively restated as shares reflecting the exchange ratio of approximately 0.703 shares of the Company per one share of OTI as established in the Merger Agreement.

The weighted average number of shares used to compute basic and diluted net loss per share excludes unvested early exercised common stock options subject to repurchase.

The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive:


	As of June 30,
	2021	2020
Redeemable convertible preferred stock	—	44,217,377
Options to purchase common stock	25,218,265	1,423,911
Unvested RSA	29,110	19,390
Restricted stock units	2,588,629	—
Unvested early exercised common stock options	2,756,906	57,874
Vested and early exercised options subject to nonrecourse notes	2,172,238	—
Preferred stock warrants	—	4,443,862
Public and private common stock warrants	15,999,996	—
Total	48,765,144	50,162,414

Income taxes	6 Months Ended
Income taxes	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Income taxes	Income taxes The Company’s income tax provision for interim periods is determined using an estimate of the Company’s annual effective tax rate, adjusted for discrete items arising in the quarter. The Company’s effective tax rate differs from the U.S. statutory tax rate primarily due to valuation allowances on the deferred tax assets as it is more likely than not that some, or all, of the Company’s deferred tax assets will not be realized. The Company continues to maintain a full valuation allowance against its net deferred tax assets. Due to tax losses and the offsetting valuation allowance, the income tax provision for the three and six months ended June 30, 2021 and 2020 was not material to the Company’s condensed consolidated financial statements.

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Revenue from Contract with Customer [Abstract]

Revenue

6 Months Ended

Jun. 30, 2021

Revenue

Revenue from sale of lidar sensor kits, which are recognized at a point in time, was $7.4 million and $2.3 million in three months ended June 30, 2021 and 2020, respectively, and $14.0 million and $4.6 million in six months ended June 30, 2021 and 2020, respectively.

The following table presents total revenues by geographic area based on the location products were shipped to and services provided (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020
United States	$	2,572	$	2,788	$	4,426	$	4,061
Americas, excluding United States	161		39		528		109
Europe, Middle East and Africa	2,931		685		6,070		1,268
Asia and Pacific	1,696		769		2,947		1,143
Total	$	7,360	$	4,281	$	13,971	$	6,581

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Schedules of Concentration of Risk

Related Party Transactions	6 Months Ended
Related Party Transactions	Jun. 30, 2021
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions See Note 5, Debt for details of promissory notes issued by the Company to certain investors of the Company (or an affiliate thereof).See Note 9, Stock-based compensation for details of partial recourse promissory notes issued by the Company to certain executives and employees.

Summary of Significant Accounting Policies (Policies)	6 Months Ended
Summary of Significant Accounting Policies (Policies)	Jun. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries (all of which are wholly owned) and have been prepared in conformity with U.S. generally accepted accounting principles (“US GAAP”) applicable to interim periods. The functional currency for the Company is the United States dollar. All intercompany balances and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements include all adjustments (consisting of only normal recurring adjustments) necessary for a fair statement of the results of operations for the periods shown. The unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements as of and for the year ended December 31, 2020 and the notes related thereto, included as Exhibit 99.1 to the Form 8-K filed with the Securities and Exchange Commission (“SEC”) on March 15, 2021, as amended on July 12, 2021. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by US GAAP. Certain information and note disclosures normally included in the audited financial statements prepared in accordance with US GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations. The results of operations for any interim period are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any other future years or interim periods.
Merger	The Merger was accounted for as a reverse recapitalization under US GAAP. Under this method of accounting, CLA is treated as the “acquired” company for financial reporting purposes. This determination is primarily based on OTI stockholders comprising a relative majority of the voting power of the Company and having the ability to nominate the members of the board of directors of the Company after the Merger, OTI’s operations prior to the Merger comprising the only ongoing operations of the Company following the Merger, and OTI’s senior management prior to the Merger comprising a majority of the senior management of the Company following the Merger. Accordingly, for accounting purposes, the financial statements of the Company represent a continuation of the financial statements of OTI with the Merger being treated as the equivalent of OTI issuing stock for the net assets of CLA, accompanied by a recapitalization whereby no goodwill or other intangible assets are recorded. Transactions and balances prior to the Merger are those of OTI. The shares and net loss per share available to holders of OTI’s common stock prior to the Merger have been retroactively restated as shares reflecting the exchange ratio established in the Merger Agreement.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements Based on our public float as of June 30, 2021, we expect to become a large accelerated filer, and lose emerging growth company status, as of December 31, 2021. As of December 31, 2021, we will be required to adopt new or revised accounting standards when they are applicable to public companies that are not emerging growth companies. In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326), to introduce a new impairment model for recognizing credit losses on financial instruments based on an estimate of current expected credit losses (“ECL”). Under the new model, an entity is required to estimate ECL on available-for-sale (AFS) debt securities only when the fair value is below the amortized cost of the asset and is no longer based on an impairment being “other-than-temporary”. The new model also requires the impairment calculation on an individual security level and requires an entity to use the present value of cash flows when estimating the ECL. The credit-related losses are required to be recognized through earnings and non-credit related losses are reported in other comprehensive income. The Company will adopt ASC 2016-13 for the December 31, 2021 annual period, with a modified retrospective application to all outstanding instruments and a cumulative effect adjustment recorded to opening retained earnings as of January 1, 2021. The Company does not believe the adoption of this new guidance will have a material impact on its consolidated financial statements. In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, which aligns the requirements for capitalizing implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The Company will adopt ASC 2018-15 for the December 31, 2021 annual period. The Company does not believe the adoption of this new guidance will have a material impact on its consolidated financial statements. In August 2020, the FASB issued ASU No. 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06). ASU 2020-06 simplifies the accounting for convertible debt and convertible preferred stock by removing the requirements to separately present certain conversion features in equity. In addition, the amendments in the ASU also simplify the guidance in ASC 815-40, Derivatives and Hedging: Contracts in Entity’s Own Equity, by removing certain criteria that must be satisfied in order to classify a contract as equity, which is expected to decrease the number of freestanding instruments and embedded derivatives accounted for as assets or liabilities. Finally, the amendments revise the guidance on calculating earnings per share, requiring use of the if-converted method for all convertible instruments and rescinding an entity’s ability to rebut the presumption of share settlement for instruments that may be settled in cash or other assets. The new standard is effective for the Company for annual periods beginning December 15, 2021. The Company is currently evaluating the impact of the adoption of this ASU on the Company’s condensed consolidated financial statements. There have been no other newly issued or newly applicable accounting pronouncements that do not require adoption until a future date that have had, or are expected to have, a significant impact on the Company’s condensed consolidated financial statements.
Concentrations of credit risk	Concentrations of credit risk Financial instruments that potentially subject the Company to credit risk consist primarily of cash, cash equivalents, and restricted cash, and accounts receivable. Cash, cash equivalents and restricted cash are deposited with federally insured commercial banks in the United States and at times cash balances may be in excess of federal insurance limits. The Company generally does not require collateral or other security deposits for accounts receivable. To reduce credit risk, the Company considers customer creditworthiness, past transaction history with the customer, current economic industry trends, and changes in customer payment terms when determining the collectability of specific customer accounts. Past due balances over 90 days and other higher risk amounts are reviewed individually for collectability. Based on management’s assessment, the Company provides for estimated uncollectible amounts through a charge to earnings and a credit to valuation allowance. Balances that remain outstanding after the Company has used reasonable collection efforts are written off through a charge to the valuation allowance and a credit to accounts receivable.

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2021

Accounting Policies [Abstract]

Accounts receivable from the Company’s major customers representing 10% or more of total accounts receivable was as follows:


	June 30, 2021	December 31, 2020
Customer A	*	13	%
Customer B	*	23	%

* Customer accounted for less than 10% of total accounts receivable in the period.

Revenue from the Company’s major customers representing 10% or more of total revenue was as follows:


	Three Months Ended June 30,			Six Months Ended June 30,
	2021	2020		2021		2020
Customer C	*	*		15	%	16	%
Customer D	*	45	%	*		30	%

* Customer accounted for less than 10% of total revenue in the period.

Purchases from the Company’s major suppliers representing 10% or more of total purchases were as follows:


	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020
Supplier A	12	%	15	%	*		*
Supplier B	14	%	16	%	15	%	14	%

* Supplier accounted for less than 10% of total purchases in the period.

Fair Value of Financial Instruments (Tables)

6 Months Ended

Jun. 30, 2021

Fair Value Disclosures [Abstract]

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

The following table provides information by level for the Company’s assets and liabilities that were measured at fair value on a recurring basis (in thousands):


	June 30, 2021
	Level 1		Level 2		Level 3		Total
Assets
Money market funds	$	238,855	$	—	$	—	$	238,855
Total financial assets	$	238,855	$	—	$	—	$	238,855
Liabilities
Warrant liabilities	$	—	$	—	$	25,471	$	25,471
Total financial liabilities	$	—	$	—	$	25,471	$	25,471


	December 31, 2020
	Level 1		Level 2		Level 3		Total
Assets
Money market funds	$	10,493	$	—	$	—	$	10,493
Total financial assets	$	10,493	$	—	$	—	$	10,493
Liabilities
Warrant liabilities	$	—	$	—	$	49,293	$	49,293
Total financial liabilities	$	—	$	—	$	49,293	$	49,293

Schedule of Changes in Fair Value of Level 3 Financial Instruments

The following table presents a summary of the changes in the fair value of the Company’s Level 3 financial instruments (in thousands):


	Redeemable Convertible Preferred Stock Warrant Liability		Redeemable Convertible Preferred Stock Tranche Liability		Private Placement Warrant Liability		Derivative Liability
Fair value as of January 1, 2020	$	(162)	$	—	$	—	$	—
Change in the fair value included in other income (expense), net	(115)		—		—		(5,308)
Recognition of preferred stock warrant and tranche liability upon issuance	(691)		(1,610)		—		—
Extinguishment of derivative liability upon conversion of convertible notes	—		—		—		5,308
Fair value as of June 30, 2020	$	(968)	$	(1,610)	$	—	$	—

Fair value as of January 1, 2021	(49,293)		—		—		—
Private placement warrant liability acquired as part of the Merger	—		—		(19,377)		—
Change in the fair value included in other income (expense), net	(8,804)		—		(6,094)		—
Issuance of preferred stock upon exercise of warrants	58,097		—		—		—
Fair value as of June 30, 2021	$	—	$	—	$	(25,471)	$	—

Balance Sheet Components (Tables)

6 Months Ended

Jun. 30, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Cash and Cash Equivalents

The Company’s cash and cash equivalents consist of the following (in thousands):


	June 30, 2021		December 31, 2020
Cash	$	1,293	$	869
Cash equivalents:
Money market funds(1)	238,855		10,493

Total cash and cash equivalents	$	240,148	$	11,362


	June 30, 2021		June 30, 2020
Cash and cash equivalents	$	240,148	$	11,438
Restricted cash, current	276		276
Restricted cash, non-current	1,004		1,280
Total cash, cash equivalents and restricted cash	$	241,428	$	12,994

Schedule of Inventory

Inventory, consisting of material, direct and indirect labor, and manufacturing overhead, consists of the following (in thousands):


	June 30, 2021		December 31, 2020
Raw materials	$	1,887	$	1,376
Work in process	1,360		1,249
Finished goods	1,474		2,192
Total inventory	$	4,721	$	4,817

Schedule of Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following (in thousands):


	June 30, 2021		December 31, 2020
Prepaid insurance	$	3,281	$	206
Prepaid expenses	1,832		694
Receivable from contract manufacturer	43		1,521
Security deposit	1,211		20
Total prepaid and other current assets	$	6,367	$	2,441

Schedule of Accrued and Other Current Liabilities

Accrued and other current liabilities consist of the following (in thousands):


	June 30, 2021		December 31, 2020
Customer deposits	48		71
Accrued compensation	2,478		1,618
Uninvoiced receipts	2,777		1,947
Other	956		485
Total accrued and other current liabilities	$	6,259	$	4,121

Warrants (Tables)

6 Months Ended

Jun. 30, 2021

Schedule of Fair Value Measurement Inputs

The redeemable convertible preferred stock warrants were valued using the following assumptions under the Black-Scholes option-pricing model:


	Initial Issuance Date			Subsequent Issuance Date			December 31, 2020			February 11, 2021			March 11, 2021
Stock price	$	5.80		$	5.80		$	7.11		$	10.27		$	8.44
Expected term (years)	10.00			9.31			2.00			2.00			2.00
Expected volatility	57.81		%	57.35		%	76.00		%	76.00		%	76.00		%
Risk-free interest rate	3.06		%	1.75		%	0.13		%	0.13		%	0.13		%
Dividend yield	0		%	0		%	0		%	0		%	0		%

The Private Placement warrants were valued using the following assumptions under the Black-Scholes option-pricing model:


	March 11, 2021			March 31, 2021			June 30, 2021
Stock price	$	12.00		$	8.50		$	12.49
Exercise price of warrant	11.5			11.5			11.5
Expected term (years)	5.00			4.95			4.7
Expected volatility	27.00		%	43.00		%	43.00		%
Risk-free interest rate	0.78		%	0.92		%	0.92		%

Redeemable Convertible Preferred and Common Stock (Tables)

6 Months Ended

Jun. 30, 2021

Schedule of Redeemable Convertible Preferred Stock

Prior to the Merger, redeemable convertible preferred stock as of December 31, 2020, consisted of the following (in thousands, except share and per share data):


	December 31, 2020
Series	Issue Price per share		Shares Authorized	Shares Issued and Outstanding	Liquidation Amount		Carrying Amount
Series B	$	0.33	131,411,372	88,434,754	$	41,791	$	39,225

Stock-based compensation (Tables)

6 Months Ended

Jun. 30, 2021

Share-based Payment Arrangement [Abstract]

Schedule of Stock Option Activity

Stock option activity for the six months ended June 30, 2021 is as follows:


	Number of Shares Underlying Outstanding Options	Weighted- Average Exercise Price per Share		Weighted- Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Outstanding—December 31, 2020	25,732,503	$	0.39	9.60	$	245,746
Options granted	645,796	10.26		9.80	$	1,440
Options exercised	(727,116)	0.13		9.00	$	6,083
Options cancelled	(432,918)	0.15
Outstanding—June 30, 2021	25,218,265	$	0.66	9.10	$	298,358
Vested and expected to vest—June 30, 2021	25,218,265	$	0.66	9.10	$	298,358
Exercisable—June 30, 2021	7,406,315	$	0.29	9.00	$	90,358

Schedule of Stock Options Valuation Assumptions


	Six Months Ended
	June 30, 2020
Expected term (years)	6.00
Expected volatility	63.19	%
Risk-free interest rate	1.03	%
Expected dividend rate	—	%

Schedule of Stock Options Outstanding and Exercisable

The following table summarizes information about stock options outstanding and exercisable at June 30, 2021.


		Options Outstanding				Options Exercisable
Exercise Price		Options Outstanding	Weighted Average Remaining Contractual Life (Years)	Weighted Average Exercise Price		Options Exercisable	Weighted Average Remaining Contractual Life (Years)	Weighted Average Exercise Price
$	0.13	6,548,017	8.90	$	0.13	3,569,978	8.88	$	0.13
$	0.15	10,455,884	9.21	$	0.15	2,537,865	9.08	$	0.15
$	0.26	35,159	0.45	$	0.26	35,159	0.45	$	0.26
$	1.00	7,524,116	9.25	$	1.00	1,254,019	9.25	$	1.00
$	3.92	7,976	0.45	$	3.92	7,976	0.45	$	3.92
$	5.80	1,318	0.45	$	5.80	1,318	0.45	$	5.80
$	10.26	645,796	9.78	$	10.26	—		$	—
		25,218,266				7,406,315

Schedule of Nonvested Restricted Stock Awards Activity

A summary of RSA activity under the 2015 Plan is as follows:


	Number of Shares	Weighted Average Grant Date Fair Value (per share)
Unvested – December 31, 2020	40,754	$	0.67
Granted during the period	—	—
Canceled during the period	—	—
Vested during the period	(11,644)	0.67
Unvested — June 30, 2021	29,110	$	0.67

Schedule of Nonvested Restricted Stock Units Activity

A summary of RSU activity is as follows:


	Number of Shares	Weighted Average Grant Date Fair Value (per share)
Unvested – December 31, 2020	—	$	—
Granted during the period	2,616,948	10.01
Canceled during the period	—	—
Vested during the period	(28,319)	11.52
Unvested — June 30, 2021	2,588,629	$	9.99

Schedule of Stock-based Compensation

The Company recognized stock-based compensation for all stock options in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020
Cost of revenue	$	133	$	59	$	251	$	101
Research and development	1,321		152		2,242		287
Sales and marketing	719		39		985		89
General and administrative	3,981		210		7,932		158
Total stock-based compensation	$	6,154	$	460	$	11,410	$	635

Net Loss Per Common Share (Tables)

6 Months Ended

Jun. 30, 2021

Earnings Per Share [Abstract]

Schedule of Net Loss Per Common Share, Basic and Diluted

The following table sets forth the computation of basic and diluted net loss per common share attributable to common stockholders (in thousands, except share and per share data):


	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020
Numerator:
Net loss	$	(32,011)	$	(11,312)	$	(52,968)	$	(30,005)
Denominator:
Weighted average shares used to compute basic and diluted net loss per share	155,923,689		19,138,365		106,070,590		13,452,766
Net loss per common share—basic and diluted	$	(0.21)	$	(0.59)	$	(0.50)	$	(2.23)

The weighted average number of shares used to compute basic and diluted net loss per share excludes unvested early exercised common stock options subject to repurchase.

Schedule of Antidilutive Securities Excluded from Computation of Net Loss Per Common Share


	As of June 30,
	2021	2020
Redeemable convertible preferred stock	—	44,217,377
Options to purchase common stock	25,218,265	1,423,911
Unvested RSA	29,110	19,390
Restricted stock units	2,588,629	—
Unvested early exercised common stock options	2,756,906	57,874
Vested and early exercised options subject to nonrecourse notes	2,172,238	—
Preferred stock warrants	—	4,443,862
Public and private common stock warrants	15,999,996	—
Total	48,765,144	50,162,414

Revenue (Tables)

6 Months Ended

Jun. 30, 2021

Revenue from Contract with Customer [Abstract]

Schedule of Disaggregation of Revenue

The following table presents total revenues by geographic area based on the location products were shipped to and services provided (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020
United States	$	2,572	$	2,788	$	4,426	$	4,061
Americas, excluding United States	161		39		528		109
Europe, Middle East and Africa	2,931		685		6,070		1,268
Asia and Pacific	1,696		769		2,947		1,143
Total	$	7,360	$	4,281	$	13,971	$	6,581

Description of Business and Basis of Presentation (Details)	Mar. 11, 2021 USD ($) $ / shares shares	Dec. 21, 2020 $ / shares shares	Jun. 30, 2021 USD ($) $ / shares shares	Mar. 10, 2021 $ / shares	Dec. 31, 2020 USD ($) $ / shares shares
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit \| $			$ 262,343,000		$ 209,375,000
Schedule of Reverse Recapitalization [Line Items]
Common stock, shares outstanding (in shares)			161,449,205		33,327,294
Common stock, shares issued (in shares)			161,449,205		33,327,294
Common stock, par value (in dollars per share) \| $ / shares		$ 0.0001	$ 0.0001		$ 0.0001
Warrants outstanding (in shares)			15,999,996
Preferred stock, par value (in dollars per share) \| $ / shares			$ 0.0001		$ 0.0001
Common stock, deemed value (in dollars per share) \| $ / shares	$ 10.00
Gross proceeds from merger and private offering \| $	$ 299,900,000
Pre-merger cost \| $	8,500,000
Offering cost \| $	26,600,000
Private Placement
Schedule of Reverse Recapitalization [Line Items]
Common stock, deemed value (in dollars per share) \| $ / shares		$ 10.00
Sale of stock, number of shares issued in transaction (in shares)		10,000,000
Sale of stock, aggregate commitment amount \| $	$ 100,000,000
Common Stock
Schedule of Reverse Recapitalization [Line Items]
Stock converted (in shares)	150,000,000
CLA \| CLA Warrants
Schedule of Reverse Recapitalization [Line Items]
Warrants outstanding (in shares)		10,000,000
CLA \| Private Placement Warrants
Schedule of Reverse Recapitalization [Line Items]
Warrants outstanding (in shares)		6,000,000
CLA \| Conversion of Class B Common Stock to Class A Common Stock
Schedule of Reverse Recapitalization [Line Items]
Ordinary shares, conversion ratio		1
CLA \| Conversion of Class A Common Stock to Common Stock
Schedule of Reverse Recapitalization [Line Items]
Ordinary shares, conversion ratio		1
CLA \| Conversion of Warrant to Ouster Common Stock
Schedule of Reverse Recapitalization [Line Items]
Warrant, conversion ratio		1
CLA \| Conversion of Canceled CLA Units to Ouster Common Stock
Schedule of Reverse Recapitalization [Line Items]
Unit, conversion ratio		1
CLA \| Conversion of Canceled CLA Units to Public Warrant
Schedule of Reverse Recapitalization [Line Items]
Unit, conversion ratio		0.5
CLA \| Common Class B
Schedule of Reverse Recapitalization [Line Items]
Common stock, shares outstanding (in shares)		5,000,000
Common stock, shares issued (in shares)		5,000,000
Common stock, par value (in dollars per share) \| $ / shares		$ 0.0001
CLA \| Common Class A
Schedule of Reverse Recapitalization [Line Items]
Common stock, shares outstanding (in shares)		25,000,000
Common stock, shares issued (in shares)		25,000,000
Common stock, par value (in dollars per share) \| $ / shares		$ 0.0001
OTI
Schedule of Reverse Recapitalization [Line Items]
Common stock, par value (in dollars per share) \| $ / shares				$ 0.00001
OTI \| Series B Preferred Stock Converted to Common Stock
Schedule of Reverse Recapitalization [Line Items]
Preferred stock, conversion ratio				1
OTI \| Series B Redeemable Convertible Preferred Stock
Schedule of Reverse Recapitalization [Line Items]
Preferred stock, par value (in dollars per share) \| $ / shares				$ 0.00001

Summary of Significant Accounting Policies - Narrative (Details)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Disaggregation of Revenue [Line Items]
Threshold period past due	90 days
Accounts Payable \| Supplier Concentration Risk \| Supplier B
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	38.00%	23.00%

Summary of Significant Accounting Policies - Schedule of Concentration Risk (Details)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Total Purchase \| Supplier Concentration Risk \| Supplier A
Concentration Risk [Line Items]
Concentration risk, percentage (less than 10%)	12.00%	15.00%	10.00%	10.00%
Total Purchase \| Supplier Concentration Risk \| Supplier B
Concentration Risk [Line Items]
Concentration risk, percentage (less than 10%)	14.00%	16.00%	15.00%	14.00%
Accounts Payable \| Supplier Concentration Risk \| Supplier B
Concentration Risk [Line Items]
Concentration risk, percentage (less than 10%)			38.00%		23.00%
Customer A \| Accounts Receivable \| Customer Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage (less than 10%)			10.00%		13.00%
Customer B \| Accounts Receivable \| Customer Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage (less than 10%)			10.00%		23.00%
Customer C \| Revenue \| Customer Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage (less than 10%)	10.00%	10.00%	15.00%	16.00%
Customer D \| Revenue \| Customer Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage (less than 10%)	10.00%	45.00%	10.00%	30.00%

Fair Value of Financial Instruments - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - Fair Value, Recurring - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Assets
Total financial assets	$ 238,855	$ 10,493
Liabilities
Warrant liabilities	25,471	49,293
Total financial liabilities	25,471	49,293
Level 1
Assets
Total financial assets	238,855	10,493
Liabilities
Warrant liabilities	0	0
Total financial liabilities	0	0
Level 2
Assets
Total financial assets	0	0
Liabilities
Warrant liabilities	0	0
Total financial liabilities	0	0
Level 3
Assets
Total financial assets	0	0
Liabilities
Warrant liabilities	25,471	49,293
Total financial liabilities	25,471	49,293
Money Market Funds
Assets
Money market funds	238,855	10,493
Money Market Funds \| Level 1
Assets
Money market funds	238,855	10,493
Money Market Funds \| Level 2
Assets
Money market funds	0	0
Money Market Funds \| Level 3
Assets
Money market funds	$ 0	$ 0

Fair Value of Financial Instruments - Schedule of Changes in the Fair Value of Level 3 Financial Instruments (Details) - Level 3 - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Redeemable Convertible Preferred Stock Warrant Liability
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value, beginning balance	$ (49,293)	$ (162)
Change in the fair value included in other income (expense), net	(8,804)	(115)
Recognition of preferred stock warrant and tranche liability upon issuance		(691)
Private placement warrant liability acquired as part of the Merger	0
Issuance of preferred stock upon exercise of warrants	58,097
Fair Value, ending balance	0	(968)
Redeemable Convertible Preferred Stock Tranche Liability
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value, beginning balance	(1,610)	0
Recognition of preferred stock warrant and tranche liability upon issuance		(1,610)
Private Placement Warrant Liability
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value, beginning balance	0	0
Change in the fair value included in other income (expense), net	(6,094)	0
Private placement warrant liability acquired as part of the Merger	(19,377)
Issuance of preferred stock upon exercise of warrants	0
Fair Value, ending balance	(25,471)	0
Derivative Liability
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value, beginning balance	0	0
Change in the fair value included in other income (expense), net	0	(5,308)
Extinguishment of derivative liability upon conversion of convertible notes		5,308
Private placement warrant liability acquired as part of the Merger	0
Issuance of preferred stock upon exercise of warrants	0
Fair Value, ending balance	$ 0	$ 0

Balance Sheet Components - Schedule of Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash	$ 1,293	$ 869
Cash equivalents:
Money market funds	238,855	10,493
Total cash and cash equivalents	$ 240,148	$ 11,362	$ 11,438

Balance Sheet Components - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Restricted cash	$ 1,300		$ 1,300		$ 1,300
Restricted cash, current	276	$ 276	276	$ 276	276
Restricted cash, non-current	1,004	1,280	1,004	1,280	1,004
Inventory write down	2,100		2,100		$ 2,700
Inventory write down	$ 100	$ 100	$ 144	$ 1,767

Balance Sheet Components - Reconciliation of Cash, Cash Equivalents and Restricted Cash Reported (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and cash equivalents	$ 240,148	$ 11,362	$ 11,438
Restricted cash, current	276	276	276
Restricted cash, non-current	1,004	1,004	1,280
Total cash, cash equivalents and restricted cash	$ 241,428	$ 12,642	$ 12,994	$ 18,405

Balance Sheet Components - Schedule of Inventory (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw materials	$ 1,887	$ 1,376
Work in process	1,360	1,249
Finished goods	1,474	2,192
Total inventory	$ 4,721	$ 4,817

Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Prepaid insurance	$ 3,281	$ 206
Prepaid expenses	1,832	694
Receivable from contract manufacturer	43	1,521
Security deposit	1,211	20
Total prepaid and other current assets	$ 6,367	$ 2,441

Balance Sheet Components - Schedule of Accrued and Other Current Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Customer deposits	$ 48	$ 71
Accrued compensation	2,478	1,618
Uninvoiced receipts	2,777	1,947
Other	956	485
Accrued and other current liabilities	$ 6,259	$ 4,121

Debt - Narrative (Details) $ / shares in Units, $ in Thousands				1 Months Ended	3 Months Ended	6 Months Ended
	Mar. 26, 2021 USD ($)	Aug. 05, 2019 USD ($) shares	Nov. 27, 2018 USD ($) $ / shares shares	Jan. 31, 2021 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2020 USD ($)	Dec. 31, 2020 USD ($)
Debt Instrument [Line Items]
Warrants, loss (gain) from fair value adjustment						$ 14,898	$ 115
Runway Loan and Security Agreement \| Secured Debt
Debt Instrument [Line Items]
Debt instrument, maximum borrowing capacity			$ 10,000
Effective interest rate					16.40%	16.40%	16.40%
Value of stock called by warrant, percentage of debt face amount			0.040
Debt instrument, face amount			$ 10,000
Fair value of warrant accounted for as debt discount			$ 100
Repayments of debt	$ 7,000
Payment of interest and fee upon extinguishment of debt	$ 400
Debt, outstanding balance					$ 0	$ 0		$ 7,000
Promissory Note \| Notes Payable, Other Payables \| Investor
Debt Instrument [Line Items]
Basis spread on variable rate				8.50%
Promissory notes, outstanding balance				$ 5,000
Series A Redeemable Convertible Preferred Stock Warrants
Debt Instrument [Line Items]
Warrants issued, number of preferred stock callable (in shares) \| shares		53,023	35,348
Warrants issued, exercise price (in dollars per share) \| $ / shares			$ 11.3518
Warrants, loss (gain) from fair value adjustment		$ 100
Series A Redeemable Convertible Preferred Stock Warrants \| Other Income (Expense), Net
Debt Instrument [Line Items]
Warrants, loss (gain) from fair value adjustment					$ 600	$ 600	$ (200)
London Interbank Offered Rate (LIBOR) \| Runway Loan and Security Agreement \| Secured Debt
Debt Instrument [Line Items]
Basis spread on variable rate			8.50%
Prime Rate \| LIBOR Rate Not Available or Applicable \| Runway Loan and Security Agreement \| Secured Debt
Debt Instrument [Line Items]
Basis spread on variable rate			6.00%
Applicable Interest Rate at the Time of Default \| In the Event of Debt Default \| Runway Loan and Security Agreement \| Secured Debt
Debt Instrument [Line Items]
Basis spread on variable rate						5.00%

Warrants - Narrative (Details)		1 Months Ended	2 Months Ended	3 Months Ended	6 Months Ended
Warrants - Narrative (Details)	Aug. 05, 2019 USD ($) $ / shares shares	Aug. 31, 2020 USD ($) $ / shares shares	May 31, 2020 $ / shares shares	Jun. 30, 2021 USD ($) shares	Jun. 30, 2021 USD ($) shares	Jun. 30, 2020 USD ($)	Mar. 11, 2021 USD ($) shares	Dec. 31, 2020 USD ($)	Apr. 03, 2020 USD ($) $ / shares shares	Nov. 27, 2018 USD ($) $ / shares shares
Class of Warrant or Right [Line Items]
Warrant, fair value				$ 25,471,000	$ 25,471,000			$ 49,293,000
Warrants, loss (gain) from fair value adjustment					$ 14,898,000	$ 115,000
Warrants outstanding (in shares) \| shares				15,999,996	15,999,996
Series B Redeemable Convertible Preferred Stock
Class of Warrant or Right [Line Items]
Issuance of redeemable convertible preferred stock (in shares) \| shares			62,505,102
Preferred stock issued (in dollars per share) \| $ / shares			$ 0.3323
Series A Redeemable Convertible Preferred Stock Warrants
Class of Warrant or Right [Line Items]
Warrants issued, number of preferred stock callable (in shares) \| shares	53,023									35,348
Warrants issued, exercise price (in dollars per share) \| $ / shares										$ 11.3518
Warrants, loss (gain) from fair value adjustment	$ 100,000
Series A Redeemable Convertible Preferred Stock Warrants \| OTI
Class of Warrant or Right [Line Items]
Warrants issued, number of preferred stock callable (in shares) \| shares	53,023									35,348
Warrants issued, exercise price (in dollars per share) \| $ / shares	$ 11.3518									$ 11.3518
Warrant, fair value	$ 100,000									$ 100,000
Series A Redeemable Convertible Preferred Stock Warrants \| Other Income (Expense), Net
Class of Warrant or Right [Line Items]
Warrants, loss (gain) from fair value adjustment				$ 600,000	$ 600,000	$ (200,000)
Series B Redeemable Convertible Preferred Stock Warrants \| OTI
Class of Warrant or Right [Line Items]
Warrants issued, number of preferred stock callable (in shares) \| shares									4,513,993
Warrants issued, exercise price (in dollars per share) \| $ / shares									$ 0.3323
Warrant, fair value									$ 700,000
Series B Redeemable Convertible Preferred Stock Warrants \| Other Income (Expense), Net \| OTI
Class of Warrant or Right [Line Items]
Warrants, loss (gain) from fair value adjustment					8,300,000
Series B Redeemable Convertible Preferred Stock Warrants \| Maximum \| OTI
Class of Warrant or Right [Line Items]
Warrant, expiration period									10 years
Redeemable Convertible Preferred Stock Tranche Right
Class of Warrant or Right [Line Items]
Warrants issued, exercise price (in dollars per share) \| $ / shares			$ 0.3323
Private Placement Warrants
Class of Warrant or Right [Line Items]
Warrants issued, exercise price (in dollars per share) \| $ / shares		$ 11.50
Private Placement Warrants \| Sponsor
Class of Warrant or Right [Line Items]
Warrants issued, number of preferred stock callable (in shares) \| shares		6,000,000
Warrant, fair value		$ 19,400,000
Warrant, expiration period		5 years
Sale of warrants, price (in dollars per share) \| $ / shares		$ 1.00
Warrant, aggregated purchase price		$ 6,000,000
Warrant, exercisable, threshold period		12 months
Number of ordinary shares called by each warrant (in shares) \| shares		1
Private Placement Warrants \| Sponsor \| Conversion of Warrant to Ouster Common Stock
Class of Warrant or Right [Line Items]
Warrant, conversion ratio							1
Private Placement Warrants \| Other Income (Expense), Net \| Sponsor
Class of Warrant or Right [Line Items]
Warrants, loss (gain) from fair value adjustment				$ 4,600,000	$ 6,100,000
Public Warrants
Class of Warrant or Right [Line Items]
Warrants issued, number of preferred stock callable (in shares) \| shares		20,000,000
Warrants issued, exercise price (in dollars per share) \| $ / shares		$ 11.50
Warrant, fair value							$ 17,900,000
Warrant, expiration period		5 years
Sale of warrants, price (in dollars per share) \| $ / shares		$ 0.01
Warrant, exercisable, threshold period		12 months
Warrant, conversion ratio		1
Warrants outstanding (in shares) \| shares							9,999,996
Exercise of warrant, threshold common stock price (in dollars per share) \| $ / shares		$ 18.00
Exercise of warrant, threshold trading days		20 days
Exercise of warrant, threshold trading-day period		30 days

Warrants - Schedule of Fair Value Measurement Inputs of Redeemable Convertible Preferred Stock Warrants (Details) - Valuation Technique, Option Pricing Model - Redeemable Convertible Preferred Stock Warrants - OTI	Mar. 11, 2021 $ / shares year	Feb. 11, 2021 $ / shares year	Dec. 31, 2020 $ / shares year	Apr. 03, 2020 $ / shares year	Nov. 27, 2018 $ / shares year
Stock price
Class of Warrant or Right [Line Items]
Warrants, fair value measurement inputs \| $ / shares	8.44	10.27	7.11	5.80	5.80
Expected term (years)
Class of Warrant or Right [Line Items]
Warrants, fair value measurement inputs \| year	2.00	2.00	2.00	9.31	10.00
Expected volatility
Class of Warrant or Right [Line Items]
Warrants, fair value measurement inputs	0.7600	0.7600	0.7600	0.5735	0.5781
Risk-free interest rate
Class of Warrant or Right [Line Items]
Warrants, fair value measurement inputs	0.0013	0.0013	0.0013	0.0175	0.0306
Dividend yield
Class of Warrant or Right [Line Items]
Warrants, fair value measurement inputs	0	0	0	0	0

Warrants - Schedule of Fair Value Measurement Inputs of Private Placement Warrants (Details) - Valuation Technique, Option Pricing Model - Private Placement Warrants	Jun. 30, 2021 $ / shares year	Mar. 31, 2021 $ / shares year	Mar. 11, 2021 $ / shares year
Stock price
Class of Warrant or Right [Line Items]
Warrants, fair value measurement inputs \| $ / shares	12.49	8.50	12.00
Exercise price of warrant
Class of Warrant or Right [Line Items]
Warrants, fair value measurement inputs	11.5	11.5	11.5
Expected term (years)
Class of Warrant or Right [Line Items]
Warrants, fair value measurement inputs	4.7	4.95	5.00
Expected volatility
Class of Warrant or Right [Line Items]
Warrants, fair value measurement inputs	0.4300	0.4300	0.2700
Risk-free interest rate
Class of Warrant or Right [Line Items]
Warrants, fair value measurement inputs	0.0092	0.0092	0.0078

Commitments and Contingencies (Details)	Jun. 30, 2021 USD ($)	Dec. 31, 2020 USD ($)	Sep. 30, 2017 letter_of_credit
Commitments and Contingencies Disclosure [Abstract]
Number of letters of credit \| letter_of_credit			2
Outstanding letter of credit	$ 1,300,000	$ 1,300,000
Third Party Contract Manufacturer
Loss Contingencies [Line Items]
Non-cancelable purchase commitments	5,700,000
Other Vendors
Loss Contingencies [Line Items]
Non-cancelable purchase commitments	6,200,000
Indemnification Agreement
Loss Contingencies [Line Items]
Potential obligations	$ 0	$ 0

Redeemable Convertible Preferred and Common Stock - Narrative (Details)

1 Months Ended

3 Months Ended

6 Months Ended

Mar. 10, 2021

$ / shares

Aug. 31, 2020

USD ($)

$ / shares

Jul. 31, 2020

USD ($)

$ / shares

Jul. 30, 2020

May 31, 2020

USD ($)

$ / shares

Apr. 30, 2020

USD ($)

$ / shares

Dec. 31, 2017

USD ($)

$ / shares

Oct. 31, 2017

USD ($)

$ / shares

Jul. 31, 2016

USD ($)

$ / shares

May 31, 2016

USD ($)

$ / shares

Apr. 30, 2016

USD ($)

$ / shares

Mar. 31, 2021

Jun. 30, 2020

USD ($)

Jun. 30, 2021

vote

$ / shares

Mar. 11, 2021

$ / shares

Dec. 31, 2020

$ / shares

Dec. 21, 2020

$ / shares

Common stock, par value (in dollars per share) | $ / shares

$ 0.0001

Preferred stock, par value (in dollars per share) | $ / shares

$ 0.0001

Common stock, shares authorized (in shares) | shares

1,000,000,000

210,956,516

Preferred stock, shares authorized (in shares) | shares

100,000,000

Common stock, shares outstanding (in shares) | shares

161,449,205

33,327,294

Warrants outstanding (in shares) | shares

15,999,996

Common stock, voting rights, number of votes per share | vote

Redeemable convertible preferred stock, shares authorized (in shares) | shares

131,411,372

Redeemable convertible preferred stock, issue price (in dollars per share) | $ / shares

$ 10.00

$ 265,000

OTI

Common stock, par value (in dollars per share) | $ / shares

$ 0.00001

Common stock, shares authorized (in shares) | shares

210,956,516

Stock, shares authorized (in shares) | shares

342,367,887

Authorized stock, par value (in dollars per share) | $ / shares

$ 0.00001

Stock issued from conversion of note (in shares) | shares

1,253,556

Convertible notes payable | $

$ 4,600,000

Investor | OTI

Stock issued from conversion of note (in shares) | shares

44,256

Convertible notes payable | $

$ 45,000

Redeemable convertible preferred stock

Redeemable convertible preferred stock, shares issued (in shares) | shares

^[1]

4,232,947

43,952,862

Redeemable convertible preferred stock | OTI

Redeemable convertible preferred stock, shares authorized (in shares) | shares

131,411,372

Series Seed Redeemable Convertible Preferred Stock | OTI

Redeemable convertible preferred stock, shares issued (in shares) | shares

445,942

563,725

1,887,253

Redeemable convertible preferred stock, issue price (in dollars per share) | $ / shares

$ 1.02

Proceeds from issuance of redeemable convertible preferred stock, net off issuance cost | $

$ 500,000

$ 600,000

$ 1,800,000

Stock issued during period, conversion of convertible securities (in shares) | shares

$ 100,000

2,941,176

Redeemable convertible preferred stock dividends (in dollars per share) | $ / shares

$ 0.0612

Liquidation preference (in dollars per share) | $ / shares

1.02

Convertible preferred stock, conversion price (in dollars per share) | $ / shares

1.02

Series A Redeemable Convertible Preferred Stock | OTI

Redeemable convertible preferred stock, shares issued (in shares) | shares

715,712

1,324,511

Redeemable convertible preferred stock, issue price (in dollars per share) | $ / shares

$ 11.3158

Proceeds from issuance of redeemable convertible preferred stock, net off issuance cost | $

$ 8,100,000

$ 14,800,000

Stock issued during period, conversion of convertible securities (in shares) | shares

$ 200,000

3,293,779

Redeemable convertible preferred stock dividends (in dollars per share) | $ / shares

0.6789

Liquidation preference (in dollars per share) | $ / shares

11.3518

Convertible preferred stock, conversion price (in dollars per share) | $ / shares

11.3518

Series B | OTI

Redeemable convertible preferred stock, shares authorized (in shares) | shares

131,411,372

Redeemable convertible preferred stock, shares issued (in shares) | shares

25,286,587

37,970,846

17,320,031

45,185,071

Redeemable convertible preferred stock, issue price (in dollars per share) | $ / shares

$ 0.3323

$ 0.33

Proceeds from issuance of redeemable convertible preferred stock, net off issuance cost | $

$ 8,400,000

$ 12,500,000

$ 5,800,000

$ 15,100,000

Redeemable convertible preferred stock dividends (in dollars per share) | $ / shares

$ 100,000

0.019938

Liquidation preference (in dollars per share) | $ / shares

0.3323

Convertible preferred stock, conversion price (in dollars per share) | $ / shares

$ 0.3323

[1]	The shares of the Company’s common and redeemable convertible preferred stock, prior to the Merger (as defined in Note 1), have been retroactively restated as shares reflecting the exchange ratio of approximately 0.703 established in the Merger as described in Note 1.

Redeemable Convertible Preferred and Common Stock - Schedule of Redeemable Convertible Preferred Stock (Details) - USD ($)	Jun. 30, 2021	Mar. 11, 2021	Dec. 31, 2020	Aug. 31, 2020	Jul. 31, 2020	May 31, 2020	Apr. 30, 2020
Class of Stock [Line Items]
Issue Price per share		$ 10.00
Shares Authorized (in shares)	0		131,411,372
Shares Issued (in shares)	0		88,434,754
Shares Outstanding (in shares)	0		88,434,754
Liquidation Amount	$ 0		$ 41,791
Carrying Amount	$ 0		$ 39,225,000
Series B \| OTI
Class of Stock [Line Items]
Issue Price per share			$ 0.33	$ 0.3323	$ 0.3323	$ 0.3323	$ 0.3323
Shares Authorized (in shares)			131,411,372
Shares Issued (in shares)			88,434,754
Shares Outstanding (in shares)			88,434,754
Liquidation Amount			$ 41,791,000
Carrying Amount			$ 39,225,000

Number of Shares Underlying Outstanding Options

Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.

+ References + Details

Stock-based compensation - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands			1 Months Ended	3 Months Ended	6 Months Ended
	Mar. 11, 2021	Oct. 12, 2020	Mar. 31, 2021	Mar. 31, 2021	Jun. 30, 2021	Jun. 30, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Options, grants in period (in shares)					645,796
Management And Employee
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Promissory notes, percentage forgiven			50.00%
Certain Executives
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Proceeds from noteholders debt			$ 300
Non-executive Noteholders
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Partial recourse promissory notes					$ 500
2015 Stock Plan \| Management And Employee
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Partial recourse promissory notes		$ 1,100
Stated interest rate		0.38%
Vested Options, exercised in period (in shares)		2,883,672
Unvested Options, exercised in period (in shares)		4,603,833
2015 Stock Plan \| Certain Executives
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Compensation cost upon forgiveness of promissory notes				$ 300	$ 300
2021 Incentive Award Plan
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Number of shares reserved for issuance (in shares)	18,558,576				15,503,561
Increase in number of shares authorized, annual increase percentage	5.00%
Number of common stock received upon vesting of each performance stock unit (in shares)	1
Options, weighted average grant date fair value (in dollars per share)					$ 5.9
Unamortized stock-based compensation expense of option					$ 30,000
Option \| 2021 Incentive Award Plan
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Option expiration period (up to)	10 years
Unamortized stock-based compensation expense, period for recognition					1 year 9 months 18 days
Option \| 2021 Incentive Award Plan \| Employee
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Minimum exercise price as percentage of fair value of shares on grant date	100.00%
Option \| 2021 Incentive Award Plan \| A Shareholder With 10% Ownership
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Option expiration period (up to)	5 years
Minimum exercise price as percentage of fair value of shares on grant date	110.00%
Shareholder ownership percentage	10.00%
Option \| 2021 Incentive Award Plan \| One Senior Advisor
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Options, grants in period (in shares)	1,614,492
Award vesting period	5 years
Threshold percentage of exercise price	130.00%
Threshold consecutive trading days	30 days
Number of shares forfeited (in shares)					1,614,492
Stock Appreciation Rights \| 2021 Incentive Award Plan
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Option expiration period (up to)	10 years
Restricted Stock
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock granted in period, other than options (in shares)					0
RSAs granted in period (in shares)					$ 0
Restricted Stock \| 2021 Incentive Award Plan
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
RSAs granted in period (in shares)					$ 0
RSAs vested in period, fair value					$ 100
Restricted Stock \| 2021 Incentive Award Plan \| Employee
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Award vesting period	4 years
Award vesting rights, vested percentage	100.00%
Restricted Stock Units (RSUs)
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock granted in period, other than options (in shares)					2,616,948
RSAs granted in period (in shares)					$ 10.01
Restricted Stock Units (RSUs) \| 2021 Incentive Award Plan
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Unamortized stock-based compensation expense, period for recognition						3 years 2 months 12 days
Unrecognized stock-based compensation expense						$ 22,100
Restricted Stock Units (RSUs) \| 2021 Incentive Award Plan \| Employee
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Award vesting period	4 years
Award vesting rights, vested percentage	100.00%
Restricted Stock Units (RSUs) \| 2021 Incentive Award Plan \| One Senior Advisor
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Award vesting period	5 years
Stock granted in period, other than options (in shares)	807,246
Restricted Stock Units (RSUs) \| 2021 Incentive Award Plan \| Several Members of the Board of Directors
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock granted in period, other than options (in shares)			152,628
Performance Stock Unit \| 2021 Incentive Award Plan \| One Senior Advisor
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Award vesting period	4 years
Stock granted in period, other than options (in shares)	807,246
Percentage of performance stock units	25.00%
Performance Stock Unit \| 2021 Incentive Award Plan \| Minimum \| One Senior Advisor
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Performance stock, stock price increase percentage	150.00%
Performance Stock Unit \| 2021 Incentive Award Plan \| Maximum \| One Senior Advisor
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Performance stock, stock price increase percentage	300.00%
Share-based Payment Arrangement, Tranche One \| Option \| 2021 Incentive Award Plan \| One Senior Advisor
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Award vesting schedule in percentage	20.00%
Share-based Payment Arrangement, Tranche One \| Restricted Stock \| 2021 Incentive Award Plan \| Employee
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Award vesting schedule in percentage	25.00%
Share-based Payment Arrangement, Tranche One \| Restricted Stock Units (RSUs) \| 2021 Incentive Award Plan \| Employee
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Award vesting schedule in percentage	25.00%
Share-based Payment Arrangement, Tranche One \| Restricted Stock Units (RSUs) \| 2021 Incentive Award Plan \| One Senior Advisor
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Award vesting schedule in percentage	20.00%
Share-based Payment Arrangement, Tranche Two \| Option \| 2021 Incentive Award Plan \| One Senior Advisor
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Award vesting schedule in percentage	20.00%
Share-based Payment Arrangement, Tranche Two \| Restricted Stock \| 2021 Incentive Award Plan \| Employee
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Award vesting schedule in percentage	25.00%
Share-based Payment Arrangement, Tranche Two \| Restricted Stock Units (RSUs) \| 2021 Incentive Award Plan \| Employee
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Award vesting schedule in percentage	25.00%
Share-based Payment Arrangement, Tranche Two \| Restricted Stock Units (RSUs) \| 2021 Incentive Award Plan \| One Senior Advisor
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Award vesting schedule in percentage	20.00%
Share-based Payment Arrangement, Tranche Three \| Option \| 2021 Incentive Award Plan \| One Senior Advisor
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Award vesting schedule in percentage	20.00%
Share-based Payment Arrangement, Tranche Three \| Restricted Stock \| 2021 Incentive Award Plan \| Employee
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Award vesting schedule in percentage	25.00%
Share-based Payment Arrangement, Tranche Three \| Restricted Stock Units (RSUs) \| 2021 Incentive Award Plan \| Employee
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Award vesting schedule in percentage	25.00%
Share-based Payment Arrangement, Tranche Three \| Restricted Stock Units (RSUs) \| 2021 Incentive Award Plan \| One Senior Advisor
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Award vesting schedule in percentage	20.00%
Share-based Payment Arrangement, Tranche Four \| Option \| 2021 Incentive Award Plan \| One Senior Advisor
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Award vesting schedule in percentage	20.00%
Share-based Payment Arrangement, Tranche Four \| Restricted Stock \| 2021 Incentive Award Plan \| Employee
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Award vesting schedule in percentage	25.00%
Share-based Payment Arrangement, Tranche Four \| Restricted Stock Units (RSUs) \| 2021 Incentive Award Plan \| Employee
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Award vesting schedule in percentage	25.00%
Share-based Payment Arrangement, Tranche Four \| Restricted Stock Units (RSUs) \| 2021 Incentive Award Plan \| One Senior Advisor
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Award vesting schedule in percentage	20.00%
Share-based Payment Arrangement, Tranche Five \| Option \| 2021 Incentive Award Plan \| One Senior Advisor
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Award vesting schedule in percentage	20.00%
Share-based Payment Arrangement, Tranche Five \| Restricted Stock Units (RSUs) \| 2021 Incentive Award Plan \| One Senior Advisor
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Award vesting schedule in percentage	20.00%

Stock-based compensation - Schedule of Stock Option Activity (Details) - USD ($)
$ / shares in Units, $ in Thousands

3 Months Ended

6 Months Ended

12 Months Ended

Mar. 31, 2020

^[1]

Jun. 30, 2021

Dec. 31, 2020

Number of shares underlying outstanding options, beginning balance (in shares)

25,732,503

Number of shares underlying outstanding options, options granted (in shares)

645,796

Number of shares underlying outstanding options, options exercised (in shares)

(423)

(727,116)

Number of shares underlying outstanding options, options cancelled (in shares)

(432,918)

Number of shares underlying outstanding options, ending balance (in shares)

25,218,265

25,732,503

Number of shares underlying outstanding options, vested and expected to vest (in shares)

25,218,265

Number of shares underlying outstanding options, exercisable (in shares)

7,406,315

Weighted- Average Exercise Price per Share

Weighted average exercise price, beginning balance (in dollars per share)

$ 0.39

Weighted average exercise price, options granted (in dollars per share)

10.26

Weighted average exercise price, options exercised (in dollars per share)

0.13

Weighted average exercise price, options cancelled (in dollars per share)

0.15

Weighted average exercise price, ending balance (in dollars per share)

0.66

$ 0.39

Weighted average exercise price, options vested and expected to vest (in dollars per share)

0.66

Weighted average exercise price, options exercisable (in dollars per share)

$ 0.29

Weighted- Average Remaining Contractual Term (in years)

Stock options outstanding, weighted average remaining contractual term

9 years 1 month 6 days

9 years 7 months 6 days

Stock options granted, weighted average remaining contractual term

9 years 9 months 18 days

Stock options exercised, weighted average remaining contractual term

9 years

Stock options vested and expected to vest, weighted average remaining contractual term

9 years 1 month 6 days

Stock options exercisable, weighted average remaining contractual term

9 years

Aggregate Intrinsic Value

Stock options outstanding, aggregate intrinsic value, beginning balance

$ 245,746

Stock options granted, aggregate intrinsic value

1,440

Stock options exercised, aggregate intrinsic value

6,083

Stock options outstanding, aggregate intrinsic value, ending balance

298,358

$ 245,746

Stock options vested and expected to vest, aggregate intrinsic value

298,358

Stock options exercisable, aggregate intrinsic value

$ 90,358

[1]	The shares of the Company’s common and redeemable convertible preferred stock, prior to the Merger (as defined in Note 1), have been retroactively restated as shares reflecting the exchange ratio of approximately 0.703 established in the Merger as described in Note 1.

Stock-based compensation - Schedule of Stock Options Valuation Assumptions (Details) - Option	6 Months Ended
	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	6 years
Expected volatility	63.19%
Risk-free interest rate	1.03%
Expected dividend rate	0.00%

Stock-based compensation - Schedule of Stock Options Outstanding and Exercisable (Details)	6 Months Ended
	Jun. 30, 2021 $ / shares shares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding (in shares) \| shares	25,218,266
Options exercisable (in shares) \| shares	7,406,315
Exercise Price at $0.13
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price, lower range limit (in dollars per share)	$ 0.13
Exercise price, upper range limit (in dollars per share)	$ 0.13
Options outstanding (in shares) \| shares	6,548,017
Options outstanding, weighted average remaining contractual life (years)	8 years 10 months 24 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 0.13
Options exercisable (in shares) \| shares	3,569,978
Options exercisable, weighted average remaining contractual life (years)	8 years 10 months 17 days
Options exercisable, weighted average exercise price (in dollars per share)	$ 0.13
Exercise Price at $0.15
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price, lower range limit (in dollars per share)	0.15
Exercise price, upper range limit (in dollars per share)	$ 0.15
Options outstanding (in shares) \| shares	10,455,884
Options outstanding, weighted average remaining contractual life (years)	9 years 2 months 15 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 0.15
Options exercisable (in shares) \| shares	2,537,865
Options exercisable, weighted average remaining contractual life (years)	9 years 29 days
Options exercisable, weighted average exercise price (in dollars per share)	$ 0.15
Exercise Price at $0.26
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price, lower range limit (in dollars per share)	0.26
Exercise price, upper range limit (in dollars per share)	$ 0.26
Options outstanding (in shares) \| shares	35,159
Options outstanding, weighted average remaining contractual life (years)	5 months 12 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 0.26
Options exercisable (in shares) \| shares	35,159
Options exercisable, weighted average remaining contractual life (years)	5 months 12 days
Options exercisable, weighted average exercise price (in dollars per share)	$ 0.26
Exercise Price at $1.00
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price, lower range limit (in dollars per share)	1.00
Exercise price, upper range limit (in dollars per share)	$ 1.00
Options outstanding (in shares) \| shares	7,524,116
Options outstanding, weighted average remaining contractual life (years)	9 years 3 months
Options outstanding, weighted average exercise price (in dollars per share)	$ 1.00
Options exercisable (in shares) \| shares	1,254,019
Options exercisable, weighted average remaining contractual life (years)	9 years 3 months
Options exercisable, weighted average exercise price (in dollars per share)	$ 1.00
Exercise Price at $3.92
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price, lower range limit (in dollars per share)	3.92
Exercise price, upper range limit (in dollars per share)	$ 3.92
Options outstanding (in shares) \| shares	7,976
Options outstanding, weighted average remaining contractual life (years)	5 months 12 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 3.92
Options exercisable (in shares) \| shares	7,976
Options exercisable, weighted average remaining contractual life (years)	5 months 12 days
Options exercisable, weighted average exercise price (in dollars per share)	$ 3.92
Exercise Price at $5.80
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price, lower range limit (in dollars per share)	5.80
Exercise price, upper range limit (in dollars per share)	$ 5.80
Options outstanding (in shares) \| shares	1,318
Options outstanding, weighted average remaining contractual life (years)	5 months 12 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 5.80
Options exercisable (in shares) \| shares	1,318
Options exercisable, weighted average remaining contractual life (years)	5 months 12 days
Options exercisable, weighted average exercise price (in dollars per share)	$ 5.80
Exercise Price at $10.26
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price, lower range limit (in dollars per share)	10.26
Exercise price, upper range limit (in dollars per share)	$ 10.26
Options outstanding (in shares) \| shares	645,796
Options outstanding, weighted average remaining contractual life (years)	9 years 9 months 10 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 10.26
Options exercisable (in shares) \| shares	0
Options exercisable, weighted average exercise price (in dollars per share)	$ 0

Stock-based compensation - Schedule of Nonvested Restricted Stock Awards Activity (Details) - Restricted Stock	6 Months Ended
	Jun. 30, 2021 $ / shares shares
Outstanding shares
Restricted stock awards, beginning balance (in shares) \| shares	40,754
Granted (in shares) \| shares	0
Canceled (in shares) \| shares	0
Vested (in shares) \| shares	(11,644)
Restricted stock awards, ending balance (in shares) \| shares	29,110
Weighted Average Grant Date Fair Value
Beginning balance (in dollars per share) \| $ / shares	$ 0.67
Granted (in dollars per share) \| $ / shares	0
Canceled (in dollars per share) \| $ / shares	0
Vested (in dollars per share) \| $ / shares	0.67
Ending balance (in dollars per share) \| $ / shares	$ 0.67

Stock-based compensation - Schedule of Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs)	6 Months Ended
	Jun. 30, 2021 $ / shares shares
Outstanding shares
Restricted stock awards, beginning balance (in shares) \| shares	0
Granted (in shares) \| shares	2,616,948
Canceled (in shares) \| shares	0
Vested (in shares) \| shares	(28,319)
Restricted stock awards, ending balance (in shares) \| shares	2,588,629
Weighted Average Grant Date Fair Value
Beginning balance (in dollars per share) \| $ / shares	$ 0
Granted (in dollars per share) \| $ / shares	10.01
Canceled (in dollars per share) \| $ / shares	0
Vested (in dollars per share) \| $ / shares	11.52
Ending balance (in dollars per share) \| $ / shares	$ 9.99

Stock-based compensation - Schedule of Stock-based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	$ 6,154	$ 460	$ 11,410	$ 635
Cost of revenue
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	133	59	251	101
Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	1,321	152	2,242	287
Sales and marketing
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	719	39	985	89
General and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	$ 3,981	$ 210	$ 7,932	$ 158

Net Loss Per Common Share - Schedule of Net Loss Per Common Share, Basic and Diluted (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020
Numerator:
Net loss	$ (32,011)	$ (20,957)	$ (11,312)	$ (18,693)	$ (52,968)	$ (30,005)
Denominator [Abstract]
Weighted-average shares used to compute basic net loss per share (in shares)	155,923,689		19,138,365		106,070,590	13,452,766
Weighted-average shares used to compute diluted net loss per share (in shares)	155,923,689		19,138,365		106,070,590	13,452,766
Net loss per common share, basic (in dollars per share)	$ (0.21)		$ (0.59)		$ (0.50)	$ (2.23)
Net loss per common share, diluted (in dollars per share)	$ (0.21)		$ (0.59)		$ (0.50)	$ (2.23)

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Net Loss Per Common Share - Narrative (Details)	Jun. 30, 2021	Jun. 30, 2020
Earnings Per Share [Abstract]
Share exchange ratio	0.703	0.703

Net Loss Per Common Share - Schedule of Antidilutive Securities Excluded from Computation of Net Loss Per Common Share (Details) - shares	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of net loss per share (in shares)	48,765,144	50,162,414
Redeemable convertible preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of net loss per share (in shares)	0	44,217,377
Options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of net loss per share (in shares)	25,218,265	1,423,911
Unvested RSA
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of net loss per share (in shares)	29,110	19,390
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of net loss per share (in shares)	2,588,629	0
Unvested early exercised common stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of net loss per share (in shares)	2,756,906	57,874
Vested and early exercised options subject to nonrecourse notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of net loss per share (in shares)	2,172,238	0
Preferred stock warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of net loss per share (in shares)	0	4,443,862
Public and private common stock warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of net loss per share (in shares)	15,999,996	0

Revenue - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Revenue - Narrative (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Disaggregation of Revenue [Line Items]
Revenue	$ 7,360	$ 4,281	$ 13,971	$ 6,581
Product
Disaggregation of Revenue [Line Items]
Revenue	7,360	2,290	13,971	4,590
Product \| Transferred at Point in Time
Disaggregation of Revenue [Line Items]
Revenue	$ 7,400	$ 2,300	$ 14,000	$ 4,600

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

Revenue - Schedule of Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Disaggregation of Revenue [Line Items]
Revenue	$ 7,360	$ 4,281	$ 13,971	$ 6,581
United States
Disaggregation of Revenue [Line Items]
Revenue	2,572	2,788	4,426	4,061
Americas, excluding United States
Disaggregation of Revenue [Line Items]
Revenue	161	39	528	109
Europe, Middle East and Africa
Disaggregation of Revenue [Line Items]
Revenue	2,931	685	6,070	1,268
Asia and Pacific
Disaggregation of Revenue [Line Items]
Revenue	$ 1,696	$ 769	$ 2,947	$ 1,143